| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | TLX101-Px (Pixclara®, Floretyrosine F18 / 18F-FET) Imaging of glioma, characterization of recurrent or progressive glioma from treatment-related changes in adult and pediatric patients Fast TrackOrphan | PDUFA | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | |
PDUFA Date example | TLX101-Px (Pixclara®, Floretyrosine F18 / 18F-FET) Imaging of glioma, characterization of recurrent or progressive glioma from treatment-related changes in adult and pediatric patients Fast TrackOrphan | PDUFA | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | |
PDUFA Date example | TLX101-Px (Pixclara®, Floretyrosine F18 / 18F-FET) Imaging of glioma, characterization of recurrent or progressive glioma from treatment-related changes in adult and pediatric patients Fast TrackOrphan | PDUFA | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology |
Recent Updates
Recently added Catalysts
Telix Pharmaceuticals Limited
$11.29
-0.62 (-5.17%)
B 60Pipeline Score Fair Value Biotech · Commercial
Market Cap
3.84 B
EPS
-0.02
P/E Ratio
-
Value Trade
973.97 K
-5.61 %
Week
-5.85 %
1 Month
17.89 %
3 Month
43.57 %
6 Month
-40.78 %
5 Year
-40.78 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
351.22 K
52 Week Range
6.28 - 12.48
% held by Insiders
-
% held by Institutions
0.94 %
Enterprise Value
3.55 B
Total Shares
339.78 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Telix Pharmaceuticals Limited
769Total events
24Upcoming
235Tier-1 (high impact)
2017 – 2029Coverage
Upcoming catalysts 2
TBD
T2R&D Day
Subscribe to view catalyst details
TBD
T1CHMP Positive Opinion
Subscribe to view catalyst details
Event history 2
TBD
◆PDUFA DateTLX101FiledRegulatory Filing
Subscribe to view catalyst details
TBD
◆PDUFA DateTLX101FiledRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-02 | TLX250-CDx (Zircaix®1,89Zr-DFO-girentuximab) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-12-02 | TLX250-CDx (Zircaix®1,89Zr-DFO-girentuximab) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-12-02 | TLX250-CDx (Zircaix®1,89Zr-DFO-girentuximab) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B60
Pipeline Score $4.7B
Pipeline ValueFair Value
Valuation Signal10
Drugs Scored1.2x
rNPV / MCap Top 90%
Small Cap (rank 95 of 938)
Percentile RankTelix Pharmaceuticals Limited holds a solid B-grade pipeline (60/100), with $7.9B risk-adjusted pipeline value, led by 131I-IPA in Neoplastic Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131I-IPA Small molecule | Neoplastic Disease | Phase 1 | NCT05450744 | 5% | $1.9B | ACTIVE NOT_RECRUITING | 12 | STALLED | D (25) | Jun 1, 2027 | MODERATE_RISK | MEDIUM Aug 14, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TLX400-Tx | advanced medullary thyroid carcinoma (MTC) | — | 2026-07-23 | disease control rate: 80%; median progression free survival: 26 months; median overall survival: 42 months Read More | EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer Read More | |
TLX400-Tx | advanced medullary thyroid carcinoma (MTC) | — | 2026-07-23 | disease control rate: 80%; median progression free survival: 26 months; median overall survival: 42 months Read More | EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer Read More | |
TLX400-Tx | advanced medullary thyroid carcinoma (MTC) | — | 2026-07-23 | disease control rate: 80%; median progression free survival: 26 months; median overall survival: 42 months Read More | EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TLX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TLX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TLX▼ -5.2%today
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
Telix Pharmaceuticals Limited will present at two upcoming healthcare conferences in New York. Dr. Christian Behrenbruch and Kevin Richardson will represent the company at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Both presentations will be available via live webcast.
Read more →TLX▲ +5.5%on this news
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix Pharmaceuticals has completed enrollment in its Phase 3 BiPASS study, which evaluates the effectiveness of its imaging agents, Illuccix and Gozellix, for prostate cancer detection before biopsy. The study enrolled 350 patients and aims to improve diagnostic accuracy while reducing unnecessary biopsies. Additionally, Telix has aligned with the FDA on a New Drug Application pathway to broaden access to PSMA-PET imaging.
Read more →TLXTelix Appoints David Gill as Chair
Telix Pharmaceuticals has appointed David Gill as the new Chair of the Board, effective immediately. Gill, who joined as a Non-Executive Director in May 2026, succeeds Dr. Mark Nelson, who will remain on the Board. With over 35 years of experience in the life sciences sector, Gill's leadership is expected to enhance Telix's growth and governance.
Read more →TLXTelix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Telix Pharmaceuticals reported strong financial results for the first half of 2026, achieving a 22% increase in revenue to US$477 million. The company highlighted significant growth in its Precision Medicine segment and successful collaborations, particularly with Regeneron. With a robust pipeline and multiple near-term catalysts, Telix is well-positioned for continued growth in the second half of the year.
Read more →TLXTelix to Host R&D Day in New York City on September 22, 2026
Telix Pharmaceuticals announced it will host an R&D Day on September 22, 2026, in New York City. The event aims to provide institutional investors and analysts with insights into Telix's therapeutic and precision medicine pipeline. Key leadership members will present, along with industry experts sharing their perspectives. Registration is required for in-person attendance.
Read more →TLXTelix H1 2026 Results: Investor Webcast Notification
Telix Pharmaceuticals Limited will release its financial results for the half-year ended June 30, 2026, on August 20, 2026. An investor webcast and conference call is scheduled for the same day. The company continues to advance its pipeline of targeted theranostics for cancer treatment, including investigational assets in pivotal-stage trials.
Read more →TLXEJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
Telix Pharmaceuticals announced promising results from a study on TLX400-Tx, a targeted therapy for advanced medullary thyroid carcinoma (MTC). The therapy showed an 80% disease control rate and acceptable safety in a real-world setting. With a median progression-free survival of 26 months, these findings support further investigation into TLX400-Tx's efficacy in larger trials.
Read more →TLX▼ -5.5%on this newsshared move
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
The publication of the ProstACT SELECT study results in the journal Cancers confirms the effectiveness of 68Ga-PSMA-PET imaging in selecting patients for TLX591-Tx therapy. TLX591-Tx, a PSMA-targeting rADC therapy, demonstrated a favorable safety profile and promising efficacy in advanced metastatic prostate cancer. The findings support ongoing evaluations in the ProstACT Global Phase 3 study.
Read more →TLXPSMA-PET imaging for prostate cancer: Exploring gallium-68 in clinical practice
Telix Pharmaceuticals discusses the advancements in gallium-68 PSMA-PET imaging for prostate cancer, highlighting its established role in patient care. Experts note its high sensitivity and specificity in detecting tumors, with significant impacts on treatment decisions. The technology's evolution and improved supply chain are set to enhance its application in clinical settings.
Read more →TLXTelix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix Pharmaceuticals reported a strong Q2 2026 performance with revenues of US$247 million, representing a 21% increase year-over-year. The company anticipates exceeding US$1 billion in revenue for FY 2026, driven by growth in its Precision Medicine segment. Key regulatory milestones were achieved, including FDA alignment on the ProstACT Global Phase 3 study. Additionally, Telix has entered a strategic collaboration with Regeneron to develop next-generation therapies.
Read more →TLXTelix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix Pharmaceuticals reported a revenue of US$247 million for Q2 2026, reflecting a 7% increase in U.S. dose volumes, primarily due to the demand for Gozellix. The company achieved significant milestones in both its Precision Medicine and Therapeutics sectors, including a strategic partnership with Regeneron. Telix is on track to meet its FY 2026 revenue guidance while continuing to invest in R&D for future growth.
Read more →TLXQ2 2026 Revenue US$247M Strong Momentum Pipeline Progress
In Q2 2026, the company reported a revenue of US$247 million, indicating strong financial performance. This growth is attributed to positive developments in their pipeline, showcasing the company's ongoing commitment to innovation and market expansion. The results reflect a robust momentum that could influence future projections.
Read more →TLXTelix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
Telix Pharmaceuticals has initiated the Phase 3 LUTEON trial by dosing the first patient with TLX250-Tx, a radiopharmaceutical therapy for relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This trial is notable as it is the first of its kind targeting CAIX in ccRCC. The study aims to assess the safety and efficacy of this innovative treatment.
Read more →TLXTelix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer
Telix Pharmaceuticals has initiated the Phase 3 LUTEON trial by dosing the first patient with TLX250-Tx, a novel radiopharmaceutical therapy for relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This study aims to evaluate the safety and efficacy of the therapy, which targets CAIX, a protein expressed in most ccRCC cases. The trial represents a significant step in developing targeted treatments for this aggressive cancer subtype.
Read more →TLXTelix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Telix has completed patient enrollment for its Phase 3 study of TLX591-Px (Illuccix®) in Japan, focusing on prostate cancer imaging. This pivotal study aims to evaluate the efficacy and safety of 68 Ga-PSMA-11 PET/CT in detecting metastatic lesions compared to conventional imaging methods. Telix is also preparing a New Drug Application and seeking Conditional Approval from Japan's PMDA.
Read more →TLXTelix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
Telix has inaugurated a state-of-the-art radiopharmaceutical facility in Melbourne, enhancing Australia's capabilities in cancer treatment. This facility will streamline the transition from research to patient care, addressing manufacturing constraints. It will also support clinical trials and training for professionals in nuclear medicine, contributing to a robust radiopharmaceutical industry in Australia.
Read more →TLXFirst Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
Telix Pharmaceuticals has initiated the OPTIMAL-e trial, dosing the first patients with TLX597-Tx for metastatic hormone-sensitive prostate cancer. This Phase 2 study evaluates the drug's effectiveness in an earlier treatment setting, aiming to enhance patient outcomes through an adaptive dosing strategy. The trial is expected to provide insights into improving disease control and quality of life.
Read more →TLXFDA Alignment to Advance ProstACT Global Phase 3 Trial
Telix Pharmaceuticals announced FDA alignment for the ProstACT Global Phase 3 trial, allowing progression to Part 2 in the U.S. The FDA confirmed the safety data from Part 1 is sufficient, and the trial will continue recruiting patients in approved regions. TLX591-Tx is expected to enhance treatment flexibility for metastatic prostate cancer patients.
Read more →TLXTelix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Telix Pharmaceuticals is hosting an educational webinar on June 29, 2026, focusing on neuro-oncology, particularly glioma and glioblastoma. The event will feature a clinical update from Dr. David N. Cade and a discussion with prominent experts in the field. Participants can register online to gain insights into future therapeutic directions.
Read more →TLXTelix and United Imaging Announce Strategic Theranostics Collaboration
Telix Pharmaceuticals and United Imaging have announced a strategic collaboration to advance integrated theranostics solutions in the U.S. This partnership will focus on combining Telix's molecular imaging products with United Imaging's advanced scanner platforms. The initial emphasis will be on TLX101-Px, a PET imaging candidate, with plans for co-development and validation of workflows to improve cancer treatment efficiency.
Read more →TLXProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix Pharmaceuticals presented positive Phase 3 data for TLX591-Tx at ASCO 2026, showing acceptable safety and tolerability in patients with metastatic castration-resistant prostate cancer (mCRPC). The study demonstrated no new safety signals and promising pharmacokinetics, supporting the drug's feasibility alongside standard-of-care therapies. Part 2 of the trial is currently underway in approved jurisdictions.
Read more →TLXEverybody has a Superhero
During Brain Tumor Awareness Month, Telix emphasizes the stories of patients like Craig Stankiewicz, a glioblastoma survivor. Craig's journey highlights the urgent need for better diagnostic and treatment tools for brain cancer. Telix is advancing innovative programs to improve patient care and outcomes. Craig's advocacy and family support exemplify resilience in the face of a challenging diagnosis.
Read more →TLXTelix at ASCO 2026
Telix will participate in the 2026 ASCO Annual Meeting in Chicago, presenting key findings from its Phase 3 study of TLX591-Tx for prostate cancer. A late-breaking oral presentation will be delivered by Dr. Pedro Barata, alongside a poster presentation on TLX250-Tx for renal cancer. Both therapies are not yet authorized for marketing.
Read more →TLXTelix at SNMMI 2026
Telix is participating in the SNMMI 2026 Annual Meeting in Los Angeles, presenting seven abstracts from its oncology portfolio. The presentations include oral sessions on imaging techniques for various cancers and poster sessions on prostate cancer and kidney cancer therapies. Attendees can visit Booth #745 to learn more about Telix's theranostic pipeline and capabilities.
Read more →TLXTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
Telix Pharmaceuticals Limited will participate in two significant conferences: the William Blair 46th Annual Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York. Dr. Christian Behrenbruch, the Managing Director and CEO, will present at both events, which will be accessible via live webcasts. This participation highlights Telix's commitment to engaging with investors and stakeholders.
Read more →TLXFighting for Every Day
During Brain Tumor Awareness Month, Telix emphasizes the need for improved diagnosis and treatment for brain cancer through personal stories. Courtney Watson shares her experience with her mother's glioblastoma diagnosis and the challenges faced. Telix is committed to enhancing its neurooncology portfolio, focusing on innovative imaging and therapeutic solutions for brain tumors.
Read more →TLXIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Telix Pharmaceuticals has announced the completion of patient enrolment in the IPAX-2 study of TLX101-Tx for newly diagnosed glioblastoma. The study reached its maximum administered dose without observing any dose-limiting toxicities. This milestone supports the ongoing development of TLX101-Tx, which is also being evaluated in a pivotal trial for recurrent glioblastoma.
Read more →TLXTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
Telix Pharmaceuticals has announced collaborations with EDAP TMS and Profound Medical to explore the use of PSMA-PET imaging in prostate cancer treatment. The focus will be on integrating imaging with minimally invasive therapies to improve patient outcomes. These partnerships aim to generate clinical evidence and optimize treatment workflows for prostate cancer care.
Read more →TLXNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Telix Pharmaceuticals has published a new analysis of Phase 3 ZIRCON trial data, indicating that TLX250-Px (Zircaix®) PET/CT imaging is highly predictive of renal malignancy across various subtypes, not just clear cell renal cell carcinoma (ccRCC). The study reported a positive predictive value of 98% and suggests potential applications in managing non-clear cell RCC. This research highlights the importance of TLX250-Px in differentiating aggressive tumors from indolent ones.
Read more →TLXTLX101-Px (Pixlumi®) MAA Accepted in EuropeUSA - EnglishAPAC - English
Telix Pharmaceuticals has announced the acceptance of its marketing authorization application (MAA) for TLX101-Px, a glioma imaging candidate, in Europe. This application aims to enhance patient access to advanced brain imaging, addressing a significant gap in the market. If approved, TLX101-Px could facilitate better diagnosis and treatment decisions for glioma patients.
Read more →TLX▲ +5.5%on this newsshared move
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix Pharmaceuticals announced that its marketing authorization application for TLX101-Px, a glioma imaging candidate, has been validated and accepted for review in Europe. The application is now in a 210-day assessment phase, aiming to enhance patient access to advanced brain imaging. If approved, TLX101-Px could significantly improve diagnostic capabilities for glioma, a common type of brain tumor.
Read more →TLXOPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
Telix Pharmaceuticals presented promising dosimetry results for TLX597-Tx at the IPCS 2026. The Phase 2 OPTIMAL-PSMA trial indicates that this PSMA-targeting radioligand therapy may enhance treatment efficacy while minimizing radiation exposure to healthy organs. The findings support the initiation of a follow-up study, OPTIMAL-E, for earlier-stage metastatic prostate cancer.
Read more →TLXEducational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Telix Pharmaceuticals is hosting an educational webinar on PSMA-targeted radionuclide therapy. Dr. David N. Cade will lead the discussion with Professor Louise Emmett, focusing on effective PSMA-targeted therapies and presenting data from the OPTIMAL-PSMA trial of TLX597-Tx. The webinar is scheduled for April 30, 2026.
Read more →TLXNotice of Annual General Meeting 2026
Telix has announced its Annual General Meeting (AGM) for shareholders, scheduled for May 21, 2026, at The Events Centre in Melbourne. The meeting will also be accessible online, allowing broader participation. Important documents such as the AGM Notice of Meeting and Proxy Form are available for download.
Read more →TLXProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Telix Pharmaceuticals announced that safety and tolerability data from its ProstACT Global Phase 3 study will be presented as a late-breaking abstract at the ASCO Annual Meeting in June 2026. The trial evaluates TLX591-Tx, a PSMA-targeted therapy, in combination with standard care for patients with metastatic castration-resistant prostate cancer. The study aims to support broader geographic adoption of this innovative treatment.
Read more →TLXTelix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix Pharmaceuticals has initiated dosing in the Phase 3 IPAX BrIGHT trial for TLX101-Tx, aimed at treating recurrent glioblastoma. This trial is significant as it represents the first radiopharmaceutical therapy to enter Phase 3 development for this aggressive cancer. The study will evaluate TLX101-Tx in combination with chemotherapy against chemotherapy alone, addressing a critical unmet need in glioblastoma treatment.
Read more →TLXTelix Successfully Prices and Upsizes US$600 Million Convertible BondsAPAC - EnglishUSA - English
Telix Pharmaceuticals has successfully upsized its convertible bonds offering from $550 million to $600 million due to strong investor demand. The bonds, which carry a 1.50% interest rate and are due in 2031, will be convertible into ordinary shares at a premium. The company also plans to repurchase a significant portion of its existing convertible bonds, enhancing its capital management strategy.
Read more →TLXTelix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds Melbourne (Australia) and
Telix Pharmaceuticals Limited announced the successful pricing and upsizing of its convertible notes offering to US$600 million, increasing from the initial US$550 million due to robust investor demand. The notes carry a 1.50% interest rate and are set to mature in April 2031. Concurrently, Telix plans to repurchase a significant portion of its existing convertible bonds, enhancing its capital management strategy. The successful issuance and repurchase reflect strong investor confidence in the company's future.
Read more →TLXTelix Refinances Convertible Bonds
Telix Pharmaceuticals has announced an offering of $550 million in convertible bonds due 2031, aimed at refinancing existing convertible bonds due 2029. The new bonds will provide cost-effective financing and are non-dilutive until conversion. Proceeds will be used primarily for repurchasing existing bonds, with any excess allocated for general corporate purposes.
Read more →TLXTelix Successfully Prices and Upsizes US$600 Million Convertible Bonds
Telix Pharmaceuticals has successfully priced and upsized its convertible bonds from $550 million to $600 million due to strong investor demand. The bonds, with a 1.50% interest rate, are set to mature in 2031 and are convertible into ordinary shares. Concurrently, Telix plans to repurchase a significant portion of its existing convertible bonds, enhancing its capital management strategy.
Read more →TLX▲ +6.6%on this newsshared move
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to develop and commercialize advanced radiopharmaceutical therapies. This partnership will leverage Telix's manufacturing capabilities and Regeneron's expertise in biologics to target multiple solid tumors. The agreement includes an upfront payment and shared commercialization costs, aiming to enhance treatment options for patients with difficult-to-treat cancers.
Read more →TLX▲ +7.6%on this newsshared move
FDA Accepts NDA for TLX101-Px (Pixclara®)
Telix Pharmaceuticals announced that the FDA has accepted its resubmitted NDA for TLX101-Px, an investigational PET imaging agent for glioma. The FDA has set a PDUFA goal date of September 11, 2026. This approval aims to improve imaging capabilities for recurrent or progressive glioma, fulfilling a significant medical need. TLX101-Px has received Orphan Drug and Fast Track designations.
Read more →TLXTelix Strengthens Board with Additional Director Appointments
Telix Pharmaceuticals Limited has announced the appointment of two new Non-Executive Directors, effective May 11, 2026, as part of its board expansion and succession planning. Interim Chair Dr. Mark Nelson expressed confidence that the new directors will enhance the board's capabilities. This move aligns with Telix's evolution as a global biopharmaceutical company.
Read more →TLX▲ +5.9%on this news· ran to +16% by day 3shared move
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix Pharmaceuticals Limited reported strong revenue growth in Q1 2026, with a 5% increase in U.S. dose volumes driven by the uptake of its products Gozellix and Illuccix. The company is advancing its therapeutics pipeline and has appointed David Gill as a new Non-Executive Director. The outlook for continued growth remains positive as Telix focuses on its strategic priorities.
Read more →TLXTelix Appoints David Gill as Non-Executive Director
Telix Pharmaceuticals has appointed David Gill as a Non-Executive Director, effective May 11, 2026. Gill, a seasoned executive with over 35 years in the life sciences sector, is expected to eventually become Chair, succeeding Mark Nelson. His extensive experience in financial leadership and governance is anticipated to strengthen Telix's board as part of its growth strategy.
Read more →TLXYou’re Not Alone
During Kidney Cancer Awareness Month, Telix shares the story of Liz Leff, a kidney cancer survivor and advocate. Diagnosed with clear cell renal cell carcinoma in 2014, Liz emphasizes the need for better diagnostics and support for patients. Her experience led her to a role at Telix, where she aims to provide the support she lacked during her journey.
Read more →TLXTelix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Telix Pharmaceuticals has partnered with IBA to enhance its U.S. manufacturing capabilities by ordering four Cyclone® KIUBE cyclotrons. This strategic move aims to strengthen supply chain resilience and enable in-house production of essential radiopharmaceuticals for cancer treatment. The collaboration is expected to improve access to advanced diagnostic tools and support the growing demand for PET imaging tracers.
Read more →TLXTelix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
Telix Pharmaceuticals has signed a contract with IBA for four Cyclone® KIUBE cyclotrons to enhance its production capabilities in the United States. This strategic investment aims to strengthen the supply chain and enable the internal manufacturing of critical therapeutic and diagnostic isotopes. The collaboration is expected to improve access to advanced diagnostic tools for cancer treatment.
Read more →TLXLive Your Life
During Kidney Cancer Awareness Month, Telix shares the poignant story of Maggie Valdes Butera and her late husband Brandon, who battled kidney cancer. Brandon's diagnosis was delayed due to misinterpretation of symptoms, leading to critical treatment delays. Maggie now advocates for better diagnostics and treatments, emphasizing the need for awareness and research in kidney cancer.
Read more →TLXTelix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Telix has resubmitted its New Drug Application for TLX101-Px, a PET imaging agent for glioma characterization, to the FDA. This resubmission follows a Type A meeting where the FDA requested additional data, which Telix believes adequately addresses previous concerns. TLX101-Px has received Orphan Drug and Fast Track designations, emphasizing its potential to meet critical medical needs.
Read more →TLXTelix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara ) Brain Cancer Imaging Candidate
Telix Pharmaceuticals has resubmitted its New Drug Application for TLX101-Px, a PET imaging agent aimed at characterizing recurrent or progressive glioma. This resubmission comes after fulfilling additional data requests from the U.S. FDA, which, in consultation with Telix, deemed necessary for addressing prior feedback. TLX101-Px holds Orphan Drug and Fast Track designations, indicating its potential to meet critical medical needs in brain cancer imaging. The company expresses optimism for swift FDA review, bolstered by extensive clinical data and the support of key medical collaborators.
Read more →TLX▲ +5.5%on this news
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Telix has announced that Part 1 of the ProstACT Global Phase 3 study met its primary objectives, confirming the safety and tolerability of TLX591-Tx in patients with mCRPC. The study involved 36 patients and assessed the therapy's integration with standard care treatments. Part 2 of the trial is already underway, aiming to expand patient enrollment significantly.
Read more →TLXInvestor Education Webinar
Telix Pharmaceuticals Limited is hosting a webinar on March 4, 2026, focusing on innovations in PSMA-PET/CT imaging for prostate cancer. Moderated by Dr. David N. Cade, the event aims to provide insights from key opinion leaders. Investors can register online for the one-hour session.
Read more →TLXInvestor Education Webinar: The Future of Prostate Imaging: What do physicians want?
Telix is hosting an investor education webinar on March 4, 2026, focusing on innovations in PSMA-PET/CT imaging for prostate cancer. The event will feature key opinion leaders discussing physician perspectives. Moderated by Dr. David N. Cade, the webinar aims to provide valuable insights for investors.
Read more →TLXTLX591-Tx: Development overview and data highlights
Telix has released a clinical data summary for TLX591-Tx, a PSMA-targeted radio antibody-drug conjugate aimed at treating metastatic castration-resistant prostate cancer. The summary includes dosimetry, safety, and efficacy data from the ProstACT SELECT Phase 1 study and outlines the ongoing ProstACT GLOBAL Phase 3 trial. TLX591-Tx has not yet received marketing authorization.
Read more →TLXTelix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
Telix Pharmaceuticals has partnered with University Hospital Essen to advance the PROMISE-PET registry, focusing on the prognostic value of PSMA-PET imaging through AI. This collaboration aims to develop AI-based prediction models for survival using extensive patient data. The initiative seeks to enhance risk stratification and clinical decision-making in prostate cancer management.
Read more →TLX▲ +14.6%on this news
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
Telix Pharmaceuticals Limited reported strong financial results for FY 2025, showcasing double-digit revenue growth and positive adjusted operating cash flow. The company is prioritizing investments in its therapeutic pipeline, particularly in late-stage trials for prostate, kidney, and brain cancer. Looking ahead, Telix aims to sustain growth through new product launches and label expansions while managing various risks associated with revenue guidance.
Read more →TLX▲ +14.6%on this newsshared move
Telix to Participate in Oppenheimer and TD Cowen Conferences
Telix Pharmaceuticals Limited will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. CEO Dr. Christian Behrenbruch will engage in a fireside chat at the Oppenheimer event, while he and Kevin Richardson will present at the TD Cowen conference. Both sessions will be available via live webcast.
Read more →TLXTelix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
Telix Pharmaceuticals has submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging candidate. This submission aims to improve patient access to advanced imaging techniques for brain cancer, addressing a significant unmet need in the diagnosis and management of gliomas. The company plans to follow up with a U.S. New Drug Application.
Read more →TLXTelix Full Year Results 2025 Investor Webcast Notification
Telix Pharmaceuticals Limited will announce its full year results for 2025 on February 20, 2026. An investor webcast is scheduled for the same day, allowing participants to engage directly with the company. Telix continues to focus on developing radiopharmaceuticals to address unmet medical needs in oncology and rare diseases.
Read more →TLXFirst Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
Telix Pharmaceuticals has announced the dosing of the first patient in a Phase 3 study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. This multicenter study aims to evaluate the efficacy and safety of 68Ga-PSMA-11 PET/CT in detecting metastatic lesions in patients with biochemically recurrent prostate cancer. The trial will enroll up to 105 patients across 11 sites, supporting future marketing authorization in Japan.
Read more →TLX▼ -5.4%on this news
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Telix Pharmaceuticals reported a revenue of US$804 million for FY 2025, driven by the successful launch of Gozellix. The company noted a 3% increase in dose volumes, indicating strong market performance. Additionally, a strategic collaboration with Varian aims to develop new clinical applications for prostate cancer treatment. Telix is well-positioned for continued growth in 2026.
Read more →TLXChinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
Telix Pharmaceuticals announced that the Chinese NMPA has accepted its New Drug Application for TLX591-Px (Illuccix), a prostate cancer imaging agent. The NDA includes data from a pivotal Phase 3 study showing a 94.8% positive predictive value for detecting tumors in patients with biochemical recurrence. This marks a significant milestone for Telix as it seeks to expand its market presence in China through its partnership with Grand Pharma.
Read more →TLXFirst U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Telix Pharmaceuticals has announced the dosing of the first patient in the BiPASS Phase 3 trial in the U.S., which aims to evaluate the effectiveness of its PSMA-PET imaging agents in diagnosing prostate cancer. The trial seeks to improve diagnostic accuracy and reduce unnecessary biopsies by integrating advanced imaging techniques. If successful, BiPASS could significantly enhance patient care and expand access to precision imaging.
Read more →TLXPresentation to J.P. Morgan Healthcare Conference
Telix will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. Dr. Christian Behrenbruch, the Managing Director and Group CEO, will deliver the presentation at 9:00 am PST. The event will be webcast live and available on demand for 30 days. Financial results for Q4 2025 will be released on January 20, 2026.
Read more →TLXZIRDOSE-CP Study of TLX250-CDx published in EJNMMI Research: Confirms Favorable Safety and Tolerability Profile in Chinese patients
The ZIRDOSE-CP Phase 1 study of TLX250-CDx has been published, confirming its safety and tolerability in Chinese patients with suspected clear cell renal cell carcinoma. This study builds on previous findings from the Phase 3 ZIRCON study, suggesting TLX250-CDx's potential as a non-invasive imaging agent. The ongoing ZIRCON-CP study aims to further validate these results in a larger cohort.
Read more →TLXTelix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
Telix Pharmaceuticals Limited will present an overview of its pipeline and commercial portfolio at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be led by Dr. Christian Behrenbruch and will be available for live streaming and on-demand viewing. Additionally, Telix plans to release its financial results for Q4 2025 on January 20, 2026.
Read more →TLXTELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
A class action lawsuit has been initiated against Telix Pharmaceuticals Limited, alleging that the company made false statements regarding its progress on prostate cancer therapies. The lawsuit claims that Telix overstated its supply chain quality and failed to disclose significant risks associated with its operations. Investors who purchased shares between February 21, 2025, and August 28, 2025, are being encouraged to discuss their legal rights with the law firm Bragar Eagel & Squire. The deadline for investors to apply to be lead plaintiffs is January 9, 2026.
Read more →TLXTelix Pharmaceuticals Ltd. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX
Telix Pharmaceuticals Ltd. is being sued for securities law violations by shareholders who allege that the company made misleading statements regarding its prostate cancer therapeutics and supply chain quality. The complaint specifically states that Telix overemphasized its progress and misrepresented its operational prospects during the class period from February 21, 2025, to August 28, 2025. Shareholders are encouraged to contact the Gross Law Firm before January 9, 2026, to explore their rights and possibly become lead plaintiffs in the case. The Gross Law Firm emphasizes the importance of transparency and corporate responsibility for protecting investor rights.
Read more →TLXTelix (TLX) 2-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Telix Pharmaceuticals Ltd. is currently facing a securities class action lawsuit initiated by Hagens Berman, which reminds investors of the approaching January 9, 2026, lead plaintiff deadline. The lawsuit arises from an SEC subpoena and an FDA Complete Response Letter citing significant manufacturing deficiencies, resulting in a notable decline in Telix's stock price. The complaint alleges that the company misrepresented the progress of its therapeutic candidates and the reliability of its supply chain. Investors who suffered losses during the specified class period are encouraged to participate in the legal action.
Read more →TLXTELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th
Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Telix Pharmaceuticals Limited for alleged misleading statements regarding its business operations. The lawsuit covers investors who acquired Telix securities between February 21, 2025, and August 28, 2025. It claims that the company overstated its progress in prostate cancer therapeutics and the quality of its supply chain. Investors are encouraged to apply to be lead plaintiffs before the deadline of January 9, 2026.
Read more →TLXTelix (TLX) 4-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Hagens Berman has reminded Telix Pharmaceuticals Ltd. investors that a deadline of January 9, 2026, is approaching for a class action lawsuit linked to a recent SEC subpoena and an unfavorable Complete Response Letter from the FDA. The lawsuit claims that Telix over-exaggerated the development of its drugs and misrepresented the reliability of its manufacturing partners. The company faced a 21% decline in its stock price following these regulatory setbacks, indicating significant investor losses. Investors who purchased shares during the class period should consider contacting the firm regarding their options.
Read more →TLXTelix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX
Telix Pharmaceuticals Ltd. is facing a class action securities lawsuit initiated by Levi & Korsinsky LLP, focusing on allegations of securities fraud. The lawsuit centers on claims that the company made false statements regarding its progress in developing prostate cancer therapeutics and misrepresented the quality of its supply chain and partners. Investors who suffered losses from February 21, 2025, to August 28, 2025, have until January 9, 2026, to seek the appointment as lead plaintiff. The lawsuit offers participation without any out-of-pocket costs for class members.
Read more →TLXPrecision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
Telix Pharmaceuticals announced positive results from its Phase 3 study of TLX591-CDx for prostate cancer imaging in China, achieving a 94.8% patient-level positive predictive value. The study's findings indicate a significant impact on treatment decisions for patients with biochemical recurrence. Additionally, Telix is progressing with resubmissions for TLX101-CDx and TLX250-CDx to the FDA, following constructive meetings.
Read more →TLXTelix Pharmaceuticals Ltd. Class Action: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX
Levi & Korsinsky, LLP has announced a class action lawsuit against Telix Pharmaceuticals Ltd. for alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025. The lawsuit claims that the company made false statements regarding its progress with prostate cancer therapies and the quality of its supply chain. Investors have until January 9, 2026, to request to be appointed as lead plaintiffs. The firm emphasizes there are no costs for class members to participate in the lawsuit.
Read more →TLX▼ -5.9%on this newsshared move
ProstACT Global Study: Status
Telix has confirmed the status of its ProstACT Global Phase 3 study for TLX591, a prostate cancer therapy. Patient enrollment for Part 1 has been completed, and the study has moved to Part 2 following a favorable review by the Independent Data Monitoring Committee. The trial has received regulatory approvals in several countries and aims to expand further into the EU.
Read more →TLX▼ -5.5%on this news· ran to -16% by day 3
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
Telix Pharmaceuticals has announced a strategic collaboration with Varian to integrate theranostic products with external beam radiation therapy (EBRT). The partnership aims to enhance patient selection and treatment personalization, particularly for prostate cancer patients using PSMA-PET imaging. This collaboration supports both company-sponsored and investigator-led clinical studies, with potential for broad clinical applications in oncology.
Read more →TLX▼ -5.5%on this news· ran to -16% by day 3shared move
TELIX CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
A class action lawsuit has been initiated against Telix Pharmaceuticals Limited, concerning securities purchased between February 21, 2025, and August 28, 2025. The suit alleges that the company made false representations regarding its prostate cancer therapeutic candidates and overstated the quality of its supply chains. Investors have until January 9, 2026, to apply for lead plaintiff status. The allegations claim that the company's statements about its business prospects were materially misleading.
Read more →TLXTelix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability--Hagens Berman
Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is under scrutiny following a securities class action lawsuit alleging misleading statements regarding the development of its prostate cancer therapeutics, TLX591 and TLX592. The lawsuit indicates that the company overstated progress and misrepresented supply chain reliability, leading to significant stock declines after regulatory setbacks. Key events included receiving a subpoena from the SEC and a Complete Response Letter from the FDA that rejected an application for TLX250-CDx, citing major deficiencies. Hagens Berman, representing aggrieved investors, seeks damages due to these alleged misrepresentations.
Read more →TLXProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
Telix Pharmaceuticals has announced the dosing of the first patient in Part 2 of its ProstACT Global Phase 3 study for TLX591, targeting metastatic castration resistant prostate cancer. This trial combines a PSMA-targeted therapy with standard treatments and aims to enroll approximately 490 patients across multiple countries. The company plans to submit Part 1 data to the FDA to facilitate expansion into U.S. sites.
Read more →TLXTelix (TLX) Facing Securities Class Action Lawsuit Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain – Hagens Berman
Telix Pharmaceuticals Ltd. is currently facing a class action lawsuit following multiple regulatory setbacks, which have significantly impacted its stock value. The lawsuit accuses the company of overstating its progress in developing therapeutic candidates TLX591 and TLX592 and misrepresenting its third-party supply chain reliability. Notably, the FDA issued a Complete Response Letter highlighting critical deficiencies, and an SEC subpoena was revealed concerning the company's drug development disclosures. Investors are being urged to come forward due to the substantial losses incurred during the affected period.
Read more →TLXTelix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX
Telix Pharmaceuticals Ltd. is facing a securities fraud class action lawsuit for allegedly making materially false statements during the period of February 21, 2025, to August 28, 2025. Accusations include overstating the company's progress with prostate cancer candidates and misrepresenting the reliability of its supply chain and partners. Shareholders are encouraged to register with the Gross Law Firm before the January 9, 2026 deadline to discuss their rights and potential participation in the case. The firm emphasizes that registration does not obligate shareholders to any costs.
Read more →TLXTelix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
Telix Pharmaceuticals Limited is facing a class action lawsuit for securities law violations related to misleading statements about its prostate cancer treatment developments and supply chain. The DJS Law Group has called on affected shareholders to participate in the case, which covers a period from February 21, 2025, to August 28, 2025. The deadline for shareholders to engage is January 9, 2026. The lawsuit claims that these false statements have caused losses to shareholders.
Read more →TLXTelix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability – Hagens Berman
Telix Pharmaceuticals (TLX) has been hit with a securities class action lawsuit following claims of misstatements regarding its prostate cancer drug candidates and supply chain reliability. The lawsuit, which covers the period from February to August 2025, alleges that the company misled investors about the developmental progress of its drugs, specifically TLX591 and TLX592. Significant stock declines followed two key events: a subpoena from the SEC and an FDA rejection of one of its applications, which revealed deficiencies in its manufacturing processes. This legal action seeks to recover damages for investors affected by the alleged securities fraud.
Read more →TLXTelix at SUO 2025
Telix will participate in the 2025 Society of Urologic Oncology Annual Meeting, which focuses on advancements in urologic cancer care. The company plans to showcase its Phase 3 precision imaging and therapeutic trials specifically targeting prostate and kidney cancer. This event is recognized as a significant platform for discussing innovations in cancer treatment.
Read more →TLXILLUCCIX désormais disponible en France après sa parution au Journal Officiel
Telix Pharmaceuticals has announced that ILLUCCIX is now officially listed in France, allowing for its clinical use in hospitals and imaging centers. This diagnostic agent, indicated for detecting prostate cancer, offers improved access and faster diagnosis for patients. The on-site preparation capability enhances imaging efficiency, addressing a significant clinical need.
Read more →TLXTelix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Telix Pharmaceuticals Limited (TLX) is currently facing a securities class action lawsuit after revealing an SEC investigation and receiving a Complete Response Letter from the FDA. The lawsuit alleges that the company misled investors regarding the progress of its prostate cancer drug candidates TLX591 and TLX592, as well as its kidney cancer candidate Zircaix. The regulatory issues have led to significant declines in the company’s stock price, raising concerns about its financial health and future prospects. Hagens Berman, the law firm leading the investigation, is urging affected investors to come forward and share their losses.
Read more →TLXTelix Opens TMS Yokohama in Japan, Commemorative Lecture HeldAPAC - EnglishJapan - Japanese
Telix Pharmaceuticals has officially opened its first cyclotron facility, Telix Manufacturing Solutions (TMS), in Yokohama, Japan. This facility aims to improve access to radiopharmaceuticals for Japanese patients, starting with TLX250-CDx for kidney cancer. The opening was marked by a lecture from Professor Jun Hatazawa, highlighting the significance of nuclear medicine in the region.
Read more →TLXTelix Opens TMS Yokohama in Japan, Commemorative Lecture Held
Telix has officially opened its first cyclotron facility in Yokohama, Japan, enhancing access to radiopharmaceuticals for local patients. The facility will initially supply TLX250-CDx for kidney cancer imaging, with plans for future products pending regulatory approval. A commemorative lecture highlighted the importance of nuclear medicine in Japan's healthcare landscape.
Read more →TLXZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Telix Pharmaceuticals announced that its TLX250-CDx imaging significantly influences clinical decision-making for almost half of patients with indeterminate renal masses, according to the ZIRCON-X study. The study, which analyzed data from 294 patients, revealed that 48.6% would have their management changed, with many potentially avoiding invasive procedures. Results will be presented at the upcoming Society of Urologic Oncology meeting.
Read more →TLXTelix Pharmaceuticals Ltd. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX
Telix Pharmaceuticals Ltd. is currently facing a class action lawsuit filed by Levi & Korsinsky, LLP for alleged securities law violations. The lawsuit targets investors affected by purported securities fraud between February 21 and August 28, 2025. It claims that the company's executives made misleading statements regarding the progress of their prostate cancer treatments and the quality of their supply chain. Affected investors have until January 9, 2026, to participate as lead plaintiffs in the case.
Read more →TLXTelix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman
Telix Pharmaceuticals Limited (TLX) is currently facing a securities class action lawsuit following significant declines in its stock price. This downturn was triggered by revelations of an SEC subpoena and a Complete Response Letter from the FDA regarding its prostate cancer therapeutic candidates. Allegations suggest that the company made misleading statements about its therapeutic pipeline while failing to disclose critical information. The ongoing litigation and regulatory scrutiny may pose further challenges for Telix as it navigates its prospects in the biopharmaceutical market.
Read more →TLXOPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
The Phase 2 OPALESCENCE trial results for TLX250-CDx in metastatic triple negative breast cancer (mTNBC) have been published, confirming its diagnostic utility. Conducted in France, the trial showed effective tumor targeting and high sensitivity in identifying lesions resistant to treatment. The findings support further exploration of CAIX-targeted imaging for broader applications in oncology.
Read more →TLXTELIX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Telix Pharmaceuticals Limited and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Telix Pharmaceuticals Limited, alleging that the company made false and misleading statements concerning its business progress and quality of supply chain partners. The lawsuit covers all individuals who purchased Telix securities between February 21, 2025, and August 28, 2025, and highlights that when accurate information was disclosed, investors suffered damage. A court deadline for potential lead plaintiffs to apply has been set for January 9, 2026.
Read more →TLXTelix to Participate in UBS and Jefferies Global Healthcare Conferences
Telix Pharmaceuticals will participate in the UBS and Jefferies Global Healthcare Conferences. CEO Kevin Richardson will engage in a fireside chat at the UBS event, while Richard Valeix will do the same at the Jefferies conference. Both sessions will be available via live webcast on Telix's Investor Relations website.
Read more →TLXTELIX PHARMACEUTICALS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Stockholders of the Ongoing Investigation
Bragar Eagel & Squire, P.C. is investigating Telix Pharmaceuticals regarding potential violations of federal securities laws, particularly related to the company's disclosures about prostate cancer therapeutic candidates. The inquiry was prompted by the receipt of a subpoena from the U.S. Securities and Exchange Commission. Following the investigation announcement, Telix's stock price experienced a significant drop of 10.44%. Investors who have suffered losses are encouraged to discuss their legal options with the law firm.
Read more →TLXTLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
Telix Pharmaceuticals has announced that its investigational PET agent TLX250-CDx has been included in updated guidelines from leading nuclear medicine organizations. This inclusion marks a significant advancement in the molecular imaging of renal masses, particularly clear cell renal cell carcinoma (ccRCC). The guidelines highlight TLX250-CDx's effectiveness in improving patient management decisions and its potential to enhance diagnostic accuracy.
Read more →TLXTLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
Telix Pharmaceuticals announced that TLX250-CDx has been included in updated guidelines by major nuclear medicine organizations for renal imaging. This investigational PET agent has shown promising results in the Phase 3 ZIRCON trial, demonstrating high sensitivity and specificity for clear cell renal cell carcinoma. The inclusion in guidelines is expected to enhance clinical adoption and improve patient outcomes.
Read more →TLXTelix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Telix Pharmaceuticals has initiated the SOLACE trial by dosing its first patient with TLX090, a radiopharmaceutical aimed at treating pain from bone metastasis. This Phase 1 trial will assess the drug's pharmacokinetics, safety, and pain relief capabilities. TLX090 is designed to offer a non-opioid alternative to existing pain management options, addressing a significant unmet need in advanced cancer care.
Read more →TLXTelix Pharmaceuticals Limited Investigated by the Portnoy Law Firm
Telix Pharmaceuticals Limited is facing an investigation by the Portnoy Law Firm over potential securities fraud. This comes after the company received a subpoena from the U.S. Securities and Exchange Commission regarding its disclosures related to prostate cancer therapeutic candidates. Following this news, Telix's stock price dropped significantly, reflecting investor concerns. The firm may file a class action on behalf of affected investors to recoup losses.
Read more →TLX▲ +9.7%on this news
TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders
Bragar Eagel & Squire, P.C. is conducting an investigation on behalf of Telix Pharmaceuticals investors due to potential violations of federal securities laws. Specifically, the firm is examining a subpoena received by Telix from the U.S. Securities and Exchange Commission regarding its disclosures related to prostate cancer therapies. This news has resulted in a substantial decline in Telix's ADR price. The law firm invites affected investors to discuss their rights and options.
Read more →TLX▲ +9.7%on this newsshared move
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix Pharmaceuticals reported a revenue of US$206 million for Q3 2025, reflecting a solid performance amid reimbursement challenges. The company has two FDA-approved imaging agents and has received CMS reimbursement for Gozellix. Telix is preparing to resubmit its NDA for a brain cancer imaging candidate and is advancing its manufacturing capabilities in Australia and Japan.
Read more →TLXTLX400 Therapy Published in Journal of Nuclear Medicine
Telix's TLX400 therapy has been published in the Journal of Nuclear Medicine, demonstrating clinical antitumor activity and a manageable safety profile in patients with advanced sarcoma. In a retrospective analysis, TLX400 achieved a disease control rate of 50% and a partial response rate of 33.3%. Despite some adverse events, the therapy shows promise for further clinical development.
Read more →TLX▲ +6.3%on this newsshared move
Telix Announces Record-Breaking Presence at EANM 2025
Telix has announced a significant milestone with 28 company-related abstract presentations scheduled for the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona. This record-breaking presence highlights the company's growing influence in the nuclear medicine sector. The conference will take place from October 4 to 8, 2025.
Read more →TLXCMS Grants Transitional Pass-Through Status for Gozellix
Telix Pharmaceuticals has received Transitional Pass-Through payment status from CMS for Gozellix, its PSMA-PET imaging agent for prostate cancer. This designation allows for separate reimbursement under the Hospital Outpatient Prospective Payment System, effective October 1, 2025. Gozellix's innovative formulation enhances patient access and simplifies payment processes, marking a significant milestone in Telix's commercial strategy.
Read more →TLX▲ +8.8%on this newsshared move
IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training
IMRA Surgical has partnered with Telix Pharmaceuticals to advance surgical training through the development of a new hydrogel model for the SENSEI drop-in gamma probe technology. This collaboration aims to enhance the integration of radio-guided surgical technologies, improve surgical outcomes, and reduce the need for traditional training methods. Specialized training courses will be offered globally to support the rollout of this innovative technology.
Read more →TLX▲ +9%on this newsshared move
Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman
Telix Pharmaceuticals Limited (NASDAQ: TLX) faces significant challenges after its American Depositary Shares dropped 16% following an FDA demand for additional data on its kidney cancer drug. This decline was compounded by a previous 10% decrease linked to an SEC subpoena regarding potential misleading statements about its drug candidates. The company also received a Complete Response Letter from the FDA identifying deficiencies related to its Biologics License Application for Zircaix®, further impacting investor confidence. Hagens Berman is investigating whether Telix misled investors about its drug development and commercial prospects.
Read more →TLXTELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Telix Pharmaceuticals Limited on behalf of its stockholders due to potential violations of federal securities laws. The investigation was announced following a subpoena received by Telix from the U.S. Securities and Exchange Commission, which seeks details regarding the company's prostate cancer drug disclosures. Following this news, Telix's stock price fell over 10%. Investors who incurred losses are encouraged to contact the law firm for further assistance.
Read more →TLXTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman
Telix Pharmaceuticals Limited is facing significant challenges as its share price plummets following a series of negative developments. The company's recent disclosure of receiving a subpoena from the SEC has raised concerns over potential misleading statements regarding its drug candidates. Moreover, the FDA has issued a Complete Response Letter for its drug Zircaix, highlighting deficiencies and requiring additional data. These developments have led to a substantial drop in the value of Telix's American Depositary Shares, prompting calls for investor scrutiny and potential legal investigations.
Read more →TLXTelix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
Telix Pharmaceuticals has initiated the Phase 3 BiPASS trial by dosing its first patient, focusing on improving prostate cancer diagnosis through MRI and PSMA-PET imaging. This study aims to enhance diagnostic accuracy and potentially reduce the need for invasive biopsies. The trial will enroll 204 patients across Australia and the U.S., marking a significant step in Telix's efforts to expand its imaging agents' indications.
Read more →TLXTelix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA
Telix has reached an agreement with the FDA regarding the resubmission of its NDA for TLX101-CDx, an investigational imaging agent for glioma. The resubmission is planned for Q4 2025 and will include additional confirmatory efficacy study analysis. The FDA has acknowledged the unmet medical need and indicated a likely expedited review. Telix is focused on bringing this important agent to U.S. patients.
Read more →TLX▼ -5.9%on this news
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Spain
Telix's Illuccix® has received marketing authorization in Spain for PSMA-PET imaging in prostate cancer. This approval allows for improved detection and localization of prostate-specific lesions, enhancing patient access to advanced diagnostic tools. Despite its benefits, access remains limited in some regions due to the scarcity of clinical sites with necessary equipment.
Read more →TLX▼ -16.1%on this newsshared move
Zircaix / TLX250-CDx FDA Approval
The FDA has approved Zircaix / TLX250-CDx, but the press release includes forward-looking statements that highlight various risks and uncertainties affecting Telix's future performance and operations.
Read more →TLXTelix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
Telix Pharmaceuticals Limited will present at two significant conferences: the Morgan Stanley 23rd Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Dr. Christian Behrenbruch, the Managing Director and Group CEO, will lead discussions at both events. These presentations will be available via live webcast and on-demand.
Read more →TLXTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
Telix Pharmaceuticals Limited (TLX) experienced a significant drop in its stock price after disclosing that it received a subpoena from the SEC. The subpoena has prompted Hagens Berman, a national shareholders rights firm, to commence an investigation into whether Telix misled investors regarding its prostate cancer therapeutic candidates. The investigation aims to examine the accuracy of statements made by Telix concerning the development and commercial prospects of its therapies, following the SEC's inquiry into their disclosures. This development raises concerns for investors who may have suffered losses as a result.
Read more →TLX▲ +10.2%on this newsshared move
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
Telix Pharmaceuticals Limited announced its financial results for the half-year ending June 30, 2025, showcasing strong revenue growth and strategic investments aimed at long-term value creation. The company is focusing on expanding its manufacturing capabilities and accelerating its therapeutic pipeline development. CEO Dr. Christian Behrenbruch expressed confidence in future product approvals and market expansions.
Read more →TLXTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman
Telix Pharmaceuticals Limited (NASDAQ: TLX) recently faced a downturn in share prices after the company disclosed receiving a subpoena from the SEC. This development initiated an investigation by national shareholders rights firm Hagens Berman, focusing on whether Telix misled investors about its drug candidates, particularly those related to prostate cancer treatments. Investors who incurred significant losses are encouraged to participate in the investigation. The situation continues to evolve as more details emerge about the company's disclosures.
Read more →TLXTelix H1 2025 Results: Investor Webcast Notification
Telix Pharmaceuticals Limited will announce its financial results for the half-year ending June 30, 2025, on August 21, 2025. An investor webcast and conference call will take place at 9:30 AM AEST on the same day. The company is committed to developing therapeutic and diagnostic radiopharmaceuticals to meet significant medical needs.
Read more →TLXTelix Reports $204M Revenue, Up 63% YOY
Telix Pharmaceuticals Limited reported a significant increase in revenue, reaching approximately $204 million for Q2 2025, a 63% rise compared to the same quarter last year. The company reaffirmed guidance for FY 2025, anticipating revenues between $770 million and $800 million. Key developments included the launch of Gozellix in the U.S. and successful recruitment for the ProstACT Global Phase 3 trial. However, Telix is facing competitive pricing pressures and is currently under investigation by the SEC.
Read more →TLXIlluccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Austria
Telix has received marketing authorization for its prostate cancer imaging agent, Illuccix, in Austria. This approval allows healthcare providers to utilize PSMA-PET imaging for detecting prostate-specific membrane antigen-positive lesions in adults. The agent is expected to enhance diagnostic accuracy and improve treatment decision-making for prostate cancer patients.
Read more →TLX▲ +7.8%on this news
Gozellix Receives Permanent HCPCS Code
Telix has announced that its PSMA PET imaging agent, Gozellix, has been granted a permanent HCPCS code by CMS, effective October 1, 2025. This code will facilitate reimbursement and billing for Gozellix, enhancing access to precision imaging for prostate cancer patients. The company believes this milestone will support wider clinical adoption and address logistical barriers in PSMA-PET imaging.
Read more →TLXTelix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses
Telix has successfully produced its first GMP-grade commercial radiopharmaceutical doses at its TMS facility in Belgium. This development marks a significant milestone in expanding access to high-quality radiopharmaceuticals for cancer patients in the region. The facility is equipped with advanced production capabilities, positioning it as a key player in the European market.
Read more →TLXTelix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix , the Company ) today announces that its Telix Manufacturing Solutions (TMS) facility...
Telix Pharmaceuticals Limited has announced that its Telix Manufacturing Solutions facility in Seneffe, Belgium, has successfully produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses. This milestone marks the launch of Telix's commercial radiopharmacy capabilities in Europe, enhancing access to innovative treatment options for cancer patients. The facility, which is one of the largest in Europe, will serve not only as a production site but also as a hub for future development in radiopharmaceuticals and isotopes. The initiative is expected to improve health outcomes in multiple regions across Belgium.
Read more →TLXTelix’s Illuccix® PSMA-PET Imaging Agent Approved in Italy
Telix's Illuccix® PSMA-PET imaging agent has received marketing authorization in Italy for detecting prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer patients. This approval allows for more accessible and efficient imaging solutions, addressing existing challenges in patient diagnosis and management. The agent is expected to improve treatment planning and patient outcomes significantly.
Read more →TLXIlluccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Belgium
Telix has received marketing authorization for Illuccix®, a PSMA-PET imaging agent, in Belgium. This approval allows healthcare providers to use this innovative tool for detecting prostate cancer lesions. The agent is expected to enhance patient outcomes by improving diagnostic accuracy and facilitating better treatment selection. The approval is backed by strong clinical data, including findings from the VISION trial.
Read more →TLXTelix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
Telix Pharmaceuticals Limited announced featured presentations and symposia at the SNMMI 2025 Annual Meeting in New Orleans. The highlights include the Global Phase 3 study of TLX591 for advanced prostate cancer and preclinical data on TLX252 in CAIX1-expressing tumors. The company is focused on advancing precision diagnostics and theranostic programs to improve cancer care for patients. Notably, Telix's sponsored symposia emphasize their innovative strategies in the field.
Read more →TLXTelix Precision Medicine Announces AlFluor Radiochemistry Platform
Telix Pharmaceuticals has launched AlFluor, a new PET radiochemistry platform that utilizes 18F-aluminium fluoride for radiolabeling. This technology enables both centralized and decentralized production methods, offering flexibility in clinical applications. Following a strategic partnership with University Hospital Ghent, Telix has access to exclusive data from a Phase 3 trial that indicates favorable diagnostic performance compared to current PSMA-PET imaging agents. The company is actively engaging with regulators to seek approval for its new imaging agent.
Read more →TLX▼ -7.8%on this news
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
Telix's Illuccix has received marketing authorization in Greece for PSMA-PET imaging in prostate cancer patients. This approval allows for improved detection and localization of prostate-specific membrane antigen-positive lesions. The agent addresses a significant need for enhanced diagnostic tools in a country where access to PSMA-PET imaging has been limited. Healthcare providers can now offer better diagnostic accuracy and treatment selection for patients.
Read more →TLXTelix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
Telix Pharmaceuticals has launched Gozellix, a next-generation PSMA-PET imaging agent for prostate cancer, now available nationwide in the U.S. This innovative product is designed for improved detection of metastases and enhanced accessibility. It establishes a new level of flexibility in distribution and production, addressing previous limitations in patient access to imaging technologies. Telix aims to provide significant advancements in prostate cancer diagnostics, addressing unmet medical needs in this area.
Read more →TLXTelix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany
Telix's Illuccix® has received marketing authorization in Germany for PSMA-PET imaging in prostate cancer patients. This approval aims to improve access to essential diagnostic tools and reduce waiting times caused by tracer shortages. The agent is expected to enhance the accuracy of prostate cancer detection and management, benefiting healthcare providers and patients alike.
Read more →TLXTelix's Illuccix® PSMA-PET Imaging Agent Approved in Germany Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix , the Company ) today announces that its prostate cancer PET[1] imaging agent,...
Telix Pharmaceuticals Limited announced that its prostate cancer PET imaging agent, Illuccix®, has received marketing authorization in Germany. This approval allows for the detection of prostate-specific membrane antigen-positive lesions in adults with prostate cancer. Illuccix® offers a significant advancement over traditional imaging methods by supporting timely diagnosis and identifying patients for targeted therapy. Moreover, its availability is expected to reduce wait times for this essential diagnostic tool in Germany's healthcare system.
Read more →TLXTelix’s Illuccix® PSMA-PET Imaging Agent Approved in Portugal
Telix has received marketing authorization in Portugal for its prostate cancer imaging agent, Illuccix®, which is used for detecting PSMA-positive lesions. This approval aims to improve diagnosis and treatment efficiency for prostate cancer patients, addressing current tracer shortages. The agent is supported by significant clinical data and will be distributed by Avanço.
Read more →TLXTelix Manufacturing Solutions (TMS) Established in Yokohama, Japan
Telix has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan, marking a key milestone in its global manufacturing strategy. This facility will serve as a hub for commercial and clinical supply, enhancing production capabilities in the Asia Pacific region. The company plans to implement advanced cyclotron technology to improve the production of medical isotopes.
Read more →TLXTelix Investor Day in New York City on June 11, 2025: Presenting KOLs
Telix Pharmaceuticals is set to host an Investor Day on June 11, 2025, in New York City, focusing on its clinical and commercial portfolio of precision medicine and therapeutic radiopharmaceuticals. Key opinion leaders in prostate cancer, glioblastoma, and renal cancer will present insights into their respective theranostic candidates. This event aims to elucidate Telix's growth opportunities and gather institutional investors and analysts for deeper engagement.
Read more →TLXTelix Highlights ProstACT Global, CUPID and STARLITE Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2025
Telix Pharmaceuticals announced the acceptance of four abstracts at the 2025 ASCO Annual Meeting, showcasing its investigational therapies for prostate and kidney cancer. Key presentations include the Phase 3 ProstACT Global study of TLX591 for metastatic prostate cancer and the Phase 2 STARLITE-2 trial of TLX250 for advanced renal cell carcinoma. These studies emphasize Telix's innovative approach in cancer treatment.
Read more →TLXTelix to Host Investor Day in New York City on June 11, 2025
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has announced it will host an Investor Day in New York City on June 11, 2025. This event aims to present growth opportunities in the company's portfolio of precision medicine and therapeutic radiopharmaceuticals. The session will feature presentations from Telix leadership and insights from Key Opinion Leaders on the company's theranostic candidates. Attendance is by advance registration specifically for institutional investors and analysts.
Read more →TLXTelix at ANZSNM Annual Scientific Meeting 2025
Telix will participate prominently in the 55th Annual Scientific Meeting of the ANZSNM in Melbourne from May 23-25, 2025. The company will present eight oral and three poster presentations focusing on its late-stage and next-generation programs. Additionally, Telix will host a Breakfast Symposium and a Nurses' Workshop, emphasizing its commitment to theranostics and collaboration in urologic and neuro-oncology.
Read more →TLXTelix Responds to Recent U.S. Government Actions- Most Favored Nation
Telix has assessed the recent U.S. Executive Order on drug pricing and believes it will have a minimal impact on its operations. The company emphasizes the unique nature of radiopharmaceuticals, which complicates pricing comparisons. Telix is committed to enhancing its U.S. presence and engaging with stakeholders to promote patient access to its innovative treatments.
Read more →TLXIlluccix China Phase 3 Study Completes Enrolment
Telix has completed patient enrolment for the Phase 3 study of TLX591-CDx (Illuccix) in China, which aims to demonstrate its efficacy in imaging prostate cancer. Conducted in partnership with Grand Pharmaceutical Group, the study enrolled 140 patients and will support a marketing authorization application with the Chinese NMPA. This study is crucial for improving prostate cancer imaging access in China.
Read more →TLXTelix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
Telix Pharmaceuticals announced that its FAP-targeting therapy candidate, TLX400, demonstrated encouraging results in a publication in the Thyroid journal. The peer-reviewed study included 73 heavily pre-treated patients with aggressive, radioiodine-resistant thyroid cancer, reporting a promising safety profile and significant efficacy. Key outcomes included median overall survival and progression-free survival of 32 and 29 months respectively. The findings suggest TLX400 may be a valuable treatment option in this challenging patient group, particularly against the backdrop of current standard therapies.
Read more →TLXTelix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
Telix has announced that its PSMA-PET imaging agent, Illuccix®, has been approved for use in the Czech Republic. This authorization allows healthcare providers to utilize the agent for detecting prostate-specific membrane antigen-positive lesions in prostate cancer patients. The approval is based on strong clinical evidence and aims to improve diagnostic accuracy and treatment planning for prostate cancer.
Read more →TLXIlluccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
Telix has announced that its prostate cancer imaging agent, Illuccix, has been granted marketing authorization by Fimea in Finland. This approval allows for the detection of PSMA-positive lesions in adults with prostate cancer, marking a significant advancement in prostate cancer management. The agent is expected to improve diagnostic accuracy and patient treatment selection.
Read more →TLXTelix’s Illuccix PSMA-PET Imaging Agent Approved in France
Telix has received marketing authorization for its PSMA-PET imaging agent, Illuccix, in France. This approval allows hospitals to conduct on-site preparations for prostate cancer detection, enhancing patient management. The agent is recognized for its superior accuracy compared to traditional imaging methods. The approval is supported by significant clinical data, addressing access challenges in prostate cancer care.
Read more →TLX▼ -6.5%on this newsshared move
Telix's Illuccix PSMA-PET Imaging Agent Approved in France Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent, Illuccix®...
Telix Pharmaceuticals has announced that its prostate cancer imaging agent, Illuccix, has received marketing authorization in France. This approval allows for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, improving upon traditional imaging methods. Illuccix is supported by comprehensive clinical data from the VISION trial, highlighting its superior accuracy in diagnosis and disease management. The company is collaborating with IRE ELiT for the marketing and promotion of the agent across French healthcare facilities.
Read more →TLXAUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®
Telix Pharmaceuticals is set to present its urologic pipeline at the 2025 AUA Annual Meeting in Las Vegas. The company will showcase four abstracts on its theranostic programs and host two sessions featuring experts in urologic oncology. Key topics include imaging for prostate cancer and advancements in kidney cancer management.
Read more →TLXTelix Reports US$186M Q1 Revenue, Up 62% YOY
Telix Pharmaceuticals Limited reported a strong Q1 2025 revenue of approximately $186 million, a 62% increase year-over-year. The revenue includes significant contributions from global sales of Illuccix and the RLS Radiopharmacies acquisition. Telix reaffirmed its FY 2025 revenue guidance of $770 million to $800 million and highlighted its ongoing R&D investments. Additionally, the company announced various positive trial results and new product launches expected in the upcoming quarters.
Read more →TLXNotice of Annual General Meeting 2025
Telix has announced its Annual General Meeting (AGM) scheduled for May 21, 2025. The meeting will take place at The Wesley Conference Centre in Sydney and will also be available online. Shareholders can access the AGM Notice, Proxy Form, and Online Guide through the provided link.
Read more →TLXIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix Pharmaceuticals has announced preliminary results from the Phase 2 IPAX-Linz study of TLX101, a therapy for recurrent high-grade glioma. The study demonstrated a median overall survival of 12.4 months, with treatment well tolerated and no serious adverse events reported. These results corroborate earlier findings from the IPAX-1 study and suggest the potential for improved patient outcomes.
Read more →TLXIlluccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden
Telix has received marketing authorization for Illuccix®, a PSMA-PET imaging agent, from the Swedish MPA. This approval allows healthcare providers in Sweden to utilize this advanced imaging technique for detecting prostate cancer. The agent is expected to enhance diagnostic accuracy and patient management, particularly in cases of biochemical recurrence.
Read more →TLXIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of...
Telix Pharmaceuticals announced promising preliminary results from the Phase 2 IPAX-Linz study of TLX101 in patients with recurrent high-grade glioma. The study demonstrated good tolerability and a median overall survival of 12.4 months, suggesting significant patient benefits. These findings support prior results from the IPAX-1 study and indicate potential advancements for treatment with TLX101. The study’s Principal Investigator and Telix's CMO emphasized the therapy’s promise for improving outcomes in patients facing historically poor prognoses.
Read more →TLXTelix Announces Cardinal Health for Gozellix Commercial Distribution
Telix Pharmaceuticals has selected Cardinal Health as a commercial distributor for Gozellix, its new FDA-approved imaging agent for prostate cancer. This partnership aims to enhance the availability of Gozellix across various U.S. locations ahead of its expected commercial launch in H1 2025. The collaboration will leverage Cardinal Health's distribution network and the ARTMS QUANTM Irradiation System to ensure efficient production of gallium-68 for Gozellix. Despite the positive developments, there are risks related to potential misinterpretation of imaging results and patient exposure to radiation.
Read more →TLXTelix Responds to Recent U.S. Government Actions
Telix has announced that recent U.S. trade tariffs will not materially affect its operations. The company boasts a strong U.S. manufacturing and distribution network, and its products are exempt from the tariffs. Additionally, Telix's New Drug Application and Biologics License Application timelines remain unchanged despite FDA workforce restructuring.
Read more →TLXTelix Appoints Paul Schaffer as Chief Technology Officer
Telix Pharmaceuticals has appointed Dr. Paul Schaffer as Chief Technology Officer, effective immediately. Dr. Schaffer previously served as CTO at ARTMS Inc. and has significant experience in life sciences and radiochemistry. In his new role, he will focus on advancing Telix's capabilities in radiopharmaceutical research and development. Both Dr. Schaffer and Telix's leadership emphasized their commitment to innovation in transforming patient care in oncology and rare diseases.
Read more →TLX▼ -15.7%on this newsshared move
Anne Whitaker Appointed as Non-Executive Director
Telix has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. With over 30 years of experience in the healthcare sector, she has held leadership roles in various pharmaceutical companies. Whitaker's expertise in risk management and governance is expected to benefit Telix as it expands globally.
Read more →TLXTelix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
Telix Pharmaceuticals has announced that the first patient has been dosed in the Phase 1 ZOLAR trial of TLX300-CDx, aimed at treating advanced soft tissue sarcoma (STS). This trial represents a key step in evaluating the safety and effectiveness of TLX300-CDx, a therapeutic radiopharmaceutical using a novel theranostic approach. The drug specifically targets PDGFRα, a protein frequently over-expressed in STS. With the trial based at the Melbourne Theranostic Innovation Centre, Telix aims to address significant unmet medical needs in the treatment of STS.
Read more →TLXFDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telix Pharmaceuticals has received FDA approval for Gozellix® (TLX007-CDx), a next-generation PSMA-PET imaging agent for prostate cancer. This agent is designed for detecting PSMA positive lesions in men with suspected metastasis or recurrence. Gozellix® features a longer shelf life and broader distribution, aiming to improve access to prostate cancer imaging across the U.S.
Read more →TLXTelix at EAU25
Telix is participating in the 40th Annual European Association of Urology Congress (EAU25) in Madrid, where it will present its Phase 3 ProstACT Global study on TLX591, a PSMA-targeting radio antibody-drug conjugate. Additionally, the company will showcase its SENSEI robotic-assisted gamma probe for radio-guided surgery. The congress runs from March 21 to 24, 2025.
Read more →TLXIlluccix® PSMA-PET-beeldvormingsagens voor prostaatkanker goedgekeurd in Nederland Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, het Bedrijf) kondigt vandaag aan dat haar PET[1]beeldvormingsagens voor prostaatkanker...
Telix Pharmaceuticals Limited announced that its PSMA-PET imaging agent, Illuccix®, has received approval for commercial use in the Netherlands. This approval allows healthcare providers to utilize a clinically validated radiopharmaceutical for the detection and localization of PSMA-positive lesions in prostate cancer patients. The introduction of Illuccix® is expected to replace traditional imaging methods due to its superior accuracy and effectiveness, thus improving patient outcomes. The approval further supports Telix's mission to enhance healthcare delivery for prostate cancer through innovative diagnostic technologies.
Read more →TLXIlluccix® Prostate Cancer PSMA-PET Imaging Agent Approved in The Netherlands
Telix has received marketing authorization for its prostate cancer imaging agent, Illuccix®, in the Netherlands. This approval allows healthcare providers to utilize PSMA-PET imaging, which is recognized for its accuracy in detecting prostate-specific membrane antigen-positive lesions. The decision is backed by robust clinical data, including results from the VISION trial, and aims to enhance patient access to effective diagnosis and treatment options.
Read more →TLXIlluccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Telix has received approval from ANVISA for Illuccix, its prostate cancer imaging agent, marking the first PSMA-PET agent authorized in Brazil. The product will be manufactured and distributed by R2PHARMA, enhancing access to advanced imaging for prostate cancer patients. A joint venture between Telix and R2PHARMA aims to further develop the radiopharmaceutical market in Brazil.
Read more →TLXIlluccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia...
Telix Pharmaceuticals has received marketing authorization for Illuccix®, a prostate cancer imaging agent, from the Brazilian Health Regulatory Agency (ANVISA). This marks the first approval of a PSMA-PET imaging agent in Brazil, highlighting the potential for enhanced detection of advanced prostate cancer. The product will be manufactured and distributed in Brazil through a joint venture with R2PHARMA, aiming to improve access to diagnostic services in the region. The Brazilian market for radiopharmaceuticals is expected to grow significantly, driven by advancements in healthcare and rising demand for innovative treatments.
Read more →TLXTelix Adds Lead-212 Isotope Production Capability Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough...
Telix Pharmaceuticals has announced the development and validation of a new generator technology for producing lead-212, enhancing yield, shelf life, and scalability. The internal IsoTherapeutics team designed this technology to produce sufficient quantities for clinical doses while minimizing waste. This advancement supports Telix's goal of developing novel alpha-emitting radiopharmaceuticals for targeted therapies, expanding their therapeutic pipeline significantly. The production method is set to be integrated into their existing manufacturing and distribution networks.
Read more →TLXTelix Adds Lead-212 Isotope Production Capability
Telix Pharmaceuticals announced the successful development and validation of a new generator technology for the production of lead-212 (212Pb). This innovative technology significantly improves upon existing methods by increasing radioactivity yield and enhancing the shelf life of the radioactive isotope. The new generators are designed for efficient production, allowing sufficient elution for up to 60 clinical doses and have the potential for further scaling. This advancement positions Telix to explore new therapeutic options in its pipeline, particularly in the targeted alpha therapy domain.
Read more →TLXTelix Completes Acquisition of FAP-targeting Theranostic Candidates
Telix has completed the acquisition of FAP-targeting theranostic candidates, enhancing its pipeline in nuclear medicine. The new candidates, developed by Professor Frank Rösch, are clinically validated and focus on treating various solid tumors, including bladder cancer. Telix aims to leverage this technology for both imaging and therapeutic applications.
Read more →TLXPatients Risk Missing Out on Revolution in Cancer Treatment: Report
A new report by Telix highlights the urgent need for Australia to invest in nuclear medicine infrastructure to support theranostics, an innovative cancer treatment. The report emphasizes that regulatory challenges and insufficient manufacturing capacity are preventing broader adoption of these therapies. With over 160,000 Australians diagnosed with cancer annually, the report calls for coordinated efforts among governments and industry to improve access to these treatments.
Read more →TLXInvestor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
Telix Therapeutics is hosting an investor webinar to present its late-stage and next-generation radiotherapeutic candidates focused on urologic oncology. The session will feature insights from leading experts in the field, covering developments in treatments for prostate and kidney cancers. The event is scheduled for March 11 and will last approximately 1.5 hours.
Read more →TLXFDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
Telix has announced that the FDA accepted the BLA for TLX250-CDx, a novel imaging agent for kidney cancer. This agent aims to accurately diagnose clear cell renal cell carcinoma (ccRCC) and has shown promising results in clinical trials. The FDA granted a Priority Review with a PDUFA date set for August 27, 2025, potentially leading to a commercial launch later that year.
Read more →TLXTelix Announces Board Renewal
Telix has announced new Director appointments as part of its Board renewal process, aimed at supporting the company's growth and governance. Tiffany Olson will succeed Kevin McCann as Board Chair, bringing expertise in radiopharmaceuticals. The changes reflect Telix's commitment to enhancing its leadership as it expands globally and prepares for a Nasdaq dual-listing.
Read more →TLX▼ -6.8%on this newsshared move
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
Telix has initiated the ProstACT Global Phase 3 trial for TLX591 at Biogenix Molecular Research Center in Miami, targeting advanced prostate cancer. The trial aims to evaluate TLX591's efficacy as a first- and second-line therapy in combination with standard treatments. This innovative approach integrates a two-dose regimen and aims to address unmet needs in metastatic castration-resistant prostate cancer care.
Read more →TLX▼ -6.8%on this newsshared move
Illuccix® Prostate Cancer Imaging Agent Approved in Luxembourg
Telix has received marketing authorization for its prostate cancer imaging agent, Illuccix®, in Luxembourg. This approval allows healthcare providers to utilize PSMA-PET imaging for detecting prostate-specific membrane antigen-positive lesions in adults. The agent is designed to enhance diagnosis and treatment selection in prostate cancer management, supported by extensive clinical data.
Read more →TLX▼ -6.8%on this newsshared move
Illuccix® Prostate Cancer Imaging Agent Approved in Malta
Telix has received marketing authorization for its prostate cancer imaging agent, Illuccix®, in Malta. This approval allows healthcare providers to utilize PSMA-PET imaging for detecting prostate-specific membrane antigen-positive lesions. The agent is expected to enhance prostate cancer management by providing more accurate imaging compared to traditional methods. The approval is based on substantial clinical data, including results from the VISION trial.
Read more →TLX▲ +7.3%on this newsshared move
Illuccix® Approved in Norway
Telix has announced that its prostate cancer imaging agent, Illuccix®, has received marketing authorization from NOMA in Norway. This approval allows for the use of PSMA-PET imaging, which offers enhanced accuracy in detecting prostate cancer lesions. The product is expected to improve access to timely diagnosis and treatment selection for patients. Illuccix® is supported by robust clinical data, including results from the VISION trial.
Read more →TLXTelix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
Telix Pharmaceuticals reported a record financial performance for FY2024, achieving a 56% increase in revenue to AU$783.2 million, primarily driven by Illuccix sales. The company is poised for significant growth in 2025 with multiple product launches and a strong therapeutic pipeline. FY2025 revenue guidance is set between AU$1.18 billion and AU$1.23 billion, reflecting continued investment in research and development.
Read more →TLXTelix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024....
Telix Pharmaceuticals has reported record financial performance for FY2024, with revenue soaring to AU$783.2 million, representing a 56% increase from the previous year. Adjusted EBITDA also rose by 70%, highlighting the company's operational efficacy. For FY2025, Telix guidance projects revenue between $1.18 billion and $1.23 billion while emphasizing an increased investment in research and development of 20% to 25%. Despite these strong results, the company's future revenue is contingent on regulatory approvals for certain products.
Read more →TLXTelix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
Telix Pharmaceuticals is set to present its urology pipeline at the ASCO Genitourinary Cancers Symposium from February 13 to 15, 2025, in San Francisco. The company will highlight four presentations, with key data on TLX592, an alpha therapy candidate for prostate cancer, and updates on ongoing trials for TLX591 and TLX250 in prostate and kidney cancers, respectively. These presentations will reflect Telix's commitment to innovating in therapeutic radiopharmaceuticals.
Read more →TLXIlluccix® Approved in the United Kingdom
Telix has received approval from the UK MHRA for its prostate cancer imaging agent, Illuccix. This agent is designed for detecting PSMA-positive lesions and is expected to improve access to imaging services amid existing supply shortages. The local production of gallium-68 allows for quicker service delivery, benefiting patients and healthcare providers across the UK.
Read more →TLXIlluccix® Approved in the United Kingdom Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare...
Telix Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency for its prostate cancer imaging agent, Illuccix. The agent, which utilizes PSMA-PET imaging, is set to replace conventional imaging methods, improving detection and localization of prostate-specific lesions. This approval aims to improve patient access and equity in prostate cancer care, particularly in light of existing shortages in PSMA-PET supplies across the UK and Europe. The product will be distributed through Telix's partner, Xiel Limited, enhancing accessibility for healthcare providers and patients.
Read more →TLXIlluccix® Approved in Denmark
Telix's Illuccix has received approval from the Danish Medicines Agency for use in prostate cancer PET imaging. This agent is designed to detect PSMA-positive lesions and represents a major improvement over traditional imaging methods. The approval is expected to enhance diagnostic accuracy and patient management in Denmark, where prostate cancer is prevalent.
Read more →TLXTelix Full Year Results 2024 Investor Webcast Notification
Telix has announced the release of its full year results and Australian Annual Report for the period ending December 31, 2024. The results will be disclosed on February 20, 2025, followed by an investor webcast and conference call on February 21, 2025. This event aims to provide insights to investors and stakeholders.
Read more →TLXStatement on impact of U.S. tariffs
Telix has stated that the current U.S. tariffs will not materially affect its business operations. The company generates most of its revenue from U.S. sales of its lead product, Illuccix, which is manufactured close to customers. Telix's strong manufacturing infrastructure and positive regulatory approvals support its outlook.
Read more →TLXTelix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix Pharmaceuticals Limited has successfully completed the acquisition of ImaginAb, Inc., gaining a pipeline of next-generation therapeutic candidates and an innovative biologics technology platform designed to enhance cancer treatment. The acquisition adds a state-of-the-art research facility and a skilled team to Telix's operations, enabling synergies with existing therapeutic development efforts. The total upfront consideration for the deal is $45 million, with potential additional payments based on future milestones. This strategic move aims to bolster Telix's capabilities in developing precision medicine and theranostic products.
Read more →TLXTelix Completes Acquisition of RLS (USA) Inc.
Telix Pharmaceuticals Limited has successfully completed the acquisition of RLS (USA) Inc., a radiopharmacy network in the U.S. This acquisition enhances Telix's capabilities by providing access to over 30 radiopharmacies and a significant operational footprint for future production. It aligns with Telix's strategy to establish an integrated radiopharmaceutical ecosystem aimed at improving patient access to innovative therapies. The acquisition was executed under previously disclosed financial terms and is expected to bolster Telix's position in the North American market.
Read more →TLXIlluccix® Receives European Approval
Telix has received European approval for Illuccix®, a PET imaging agent for prostate cancer. This decision follows a positive assessment from the German Competent Authority and allows for a commercial launch across Europe. Illuccix is recognized in clinical guidelines for its superior accuracy in prostate cancer management.
Read more →TLXIlluccix® Receives European Approval Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing...
Telix Pharmaceuticals has achieved a positive decision for the marketing authorization of its lead imaging product, Illuccix, across the European Economic Area. This approval follows the Final Assessment Report from Germany, which serves as the Reference Member State. Illuccix, a gallium-68 labeled product for detecting prostate cancer, will now move into the national phase for implementation in various European countries. The decision endorses PSMA-PET imaging as a major advancement in managing prostate cancer, replacing traditional imaging techniques.
Read more →TLXScintimun® Commercialization Partnership with Curium Pharma
Telix has partnered with Curium Pharma to regain marketing and distribution rights for Scintimun, a diagnostic radiopharmaceutical. This move follows a strategic review aimed at enhancing sales and expanding clinical applications. The partnership also includes a manufacturing agreement with Curium, which has previously handled the product. Telix plans to leverage Scintimun for improved patient selection in bone marrow conditioning.
Read more →TLXScintimun® Commercialization Partnership with Curium Pharma Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma...
Telix Pharmaceuticals Limited has announced an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun, a diagnostic radiopharmaceutical. This partnership marks a strategic move for Telix, enabling the company to handle sales and marketing internally while expanding the commercial distribution of Scintimun. The product, which has demonstrated superior sensitivity over conventional diagnostic methods, is intended to serve various applications in infection, immunology, and oncology. Curium will also manufacture Scintimun, leveraging their capabilities in nuclear medicine.
Read more →TLXTelix Exceeds FY24 Guidance with US$142M Q4 Revenue
Telix Pharmaceuticals reported a significant increase in revenue for Q4 2024, achieving approximately US$142 million—an increase of 46% from the same quarter last year. The company's total FY2024 revenue also exceeded its guidance, reaching around US$517 million. Telix's growth is primarily driven by sales of its diagnostic radiopharmaceutical, Illuccix. Looking ahead, Telix aims to launch several imaging products and progress its therapeutic candidates in pivotal trials in 2025.
Read more →TLXTelix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) announced that Dr. Christian Behrenbruch, the Managing Director and Group CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 15, 2025, at 2:15 pm PST. This event is significant for Telix as it provides a platform to highlight its innovations in therapeutic and diagnostic radiopharmaceuticals to potential investors and industry stakeholders. The webcast of the presentation will be available on demand following the event.
Read more →TLXTelix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix has entered an asset purchase agreement with ImaginAb to acquire a pipeline of next-generation therapeutic candidates and a novel biologics technology platform. This acquisition aims to enhance Telix's existing capabilities in antibody engineering and preclinical development. The new assets will allow Telix to expand its therapeutics pipeline into new disease areas, addressing unmet clinical needs.
Read more →TLXTelix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with...
Telix Pharmaceuticals has announced the acquisition of a pipeline of next-generation therapeutic assets from ImaginAb, which includes a proprietary biologics technology platform. This strategic move is aimed at expanding Telix's capabilities in innovative therapeutics targeting high-value cancer indicators. The deal amounts to US$45 million, with potential future payments up to US$185 million contingent on development milestones. The acquisition is positioned to enhance Telix's pipeline and address unmet medical needs in oncology, although it is contingent on regulatory and other approvals.
Read more →TLXNOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
The NOBLE Registry's results for TLX599-CDx have been published, showcasing its potential in prostate cancer imaging. The study involved 40 patients across six countries, with 42.5% experiencing management changes due to SPECT imaging. This technology aims to enhance access to PSMA imaging, particularly in regions with limited PET scanner availability. The findings suggest a promising future for technetium-99m-based imaging.
Read more →TLXNOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for...
Telix Pharmaceuticals and the Oncidium foundation have published results from the NOBLE Registry for TLX599-CDx imaging in prostate cancer in EJNMMI Reports. The registry aims to enhance access to PSMA imaging through globally distributed SPECT technology. Initial findings from 40 patients suggest a notable management change in 42.5% of cases due to the imaging technique. The registry's goal is to provide a widely available solution for prostate cancer patients lacking access to traditional PET imaging.
Read more →TLXTelix Files TLX250-CDx (Zircaix ) BLA for Kidney Cancer Imaging
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) for its investigational PET imaging agent TLX250-CDx to the FDA. This product aims to improve the diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most aggressive form of kidney cancer. Notably, TLX250-CDx, if approved, would become the first targeted PET agent for kidney cancer in the United States. The company has reported promising data from its Phase III ZIRCON trial, meeting all primary and secondary endpoints.
Read more →TLXTelix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
Telix has successfully installed two new cyclotrons at its Manufacturing Solutions facility in Brussels South, Belgium. This development will enable on-site production of radioisotopes and patient doses starting in 2025. The facility aims to become a key manufacturing site for the EMEA region, supporting both clinical supply and research initiatives. Commissioning is set to begin in early Q1 2025, with the first commercial production expected in H2 2025.
Read more →TLXTelix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new...
Telix Pharmaceuticals Limited has announced the completion of the installation of two new cyclotrons at its Telix Manufacturing Solutions site in Brussels South, Belgium. These cyclotrons will facilitate the on-site production of radioisotopes and patient doses starting in 2025, making TMS a significant facility for nuclear medicine in the EMEA region. The installations include one cyclotron focused on clinical supply and another dedicated to research and development. Telix anticipates that this upgrade will help meet the increasing demand for radiopharmaceutical procedures in Europe.
Read more →TLX▲ +7%on this news
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
Telix and Grand Pharma have initiated the Phase III ZIRCON-CP trial for TLX250-CDx, focusing on imaging clear cell renal cell carcinoma in Chinese patients. The trial, which aims to enroll up to 82 patients, builds on the success of the global ZIRCON trial. This initiative seeks to validate the diagnostic capabilities of TLX250-CDx in the Chinese market, where kidney cancer incidence is rising.
Read more →TLXTelix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Telix to Add FAP-Targeting Candidates to Theranostic Pipeline Melbourne (Australia) - 19 November
Telix Pharmaceuticals Limited has announced the expansion of its theranostic pipeline by acquiring FAP-targeting candidates aimed at treating bladder cancer. The new assets, developed in collaboration with Professor Frank Roesch and his team, have shown clinical validation across multiple solid tumors. The transaction involves an initial cash payment and potential future milestones based on clinical development. However, the completion of these agreements is contingent upon regulatory approvals and customary conditions.
Read more →TLXTelix to Add FAP-Targeting Candidates to Theranostic Pipeline
Telix is expanding its theranostic pipeline by adding new assets that target Fibroblast Activation Protein (FAP), a promising marker in cancer treatment. The initial focus will be on bladder cancer, complementing existing programs for kidney and prostate cancers. The assets have been clinically validated and are expected to improve therapeutic outcomes for cancer patients.
Read more →TLXTelix to Add FAP-Targeting Candidates to Theranostic Pipeline Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets...
Telix Pharmaceuticals Limited has announced its plans to expand its theranostic pipeline by adding new candidates targeting Fibroblast Activation Protein (FAP), which is important in nuclear medicine for cancer treatment. The company's initial focus will be on bladder cancer to strengthen its urology franchise. Telix has formed exclusive agreements with SCV GmbH and Medianezia GmbH to access these assets, involving significant financial commitments tied to clinical development milestones. Closing these agreements will be subject to customary conditions including regulatory approvals.
Read more →TLXTelix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Telix ADSs Commence Trading on Nasdaq Melbourne (Australia) - 14 November 2024 . Telix Pharmaceut
Telix Pharmaceuticals Limited has announced that its American Depository Shares (ADSs) have begun trading on the Nasdaq Global Select Market under the ticker symbol TLX. This strategic move is designed to enhance the company's presence in the U.S. market and offer streamlined access to its shares for a wider range of investors. While existing shareholders transition their shares to ADSs, Telix maintains its primary listing on the Australian Securities Exchange (ASX). This listing represents a significant milestone in Telix's growth trajectory within the biopharmaceutical industry.
Read more →TLXTelix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
Telix has partnered with Eckert & Ziegler SE to utilize their cyclotron technology for producing actinium-225, enhancing Telix's capabilities in developing targeted alpha therapies. This collaboration aims to meet the growing demand for actinium-225 and supports Telix's strategic focus on advancing its alpha therapy pipeline. The partnership combines the strengths of both companies in radiopharmaceuticals.
Read more →TLXTelix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
Telix Pharmaceuticals has announced a collaboration with Eckert & Ziegler for the production of actinium-225 using advanced cyclotron-based technology. This partnership aims to enhance Telix's capacity to produce this critical isotope, supporting the development of targeted alpha therapies. The move aligns with Telix's strategic focus on radiopharmaceuticals, particularly as demand for actinium-225 is expected to grow significantly. Both companies believe that this collaboration will streamline the supply of actinium-based radiotherapeutics and expand Telix's manufacturing capabilities worldwide.
Read more →TLXTelix ADSs Commence Trading on Nasdaq
Telix Pharmaceuticals Limited has announced that its American Depository Shares (ADSs) have begun trading on the Nasdaq Global Select Market under the ticker symbol 'TLX.' This move is expected to complement the company's primary listing on the ASX, enhancing access to Telix's shares for U.S. and global investors. The CEO emphasized that the Nasdaq listing is an important milestone reflecting the company's growth and leadership in radiopharmaceuticals.
Read more →TLXTelix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
Telix Pharmaceuticals has welcomed a significant decision from the U.S. Centers for Medicare & Medicaid Services (CMS) that will allow separate payments for specialized diagnostic radiopharmaceuticals in the hospital outpatient setting, effective from 2025. This change aims to facilitate equitable access to advanced imaging agents for all patients, ensuring consistent reimbursement following the expiry of pass-through payment status. The new rule will notably benefit Telix's pipeline products, including TLX007-CDx for prostate cancer imaging, which could further enhance patient access to clinically significant diagnostic tools. The announcement underscores Telix's commitment to innovation in the field of precision medicine.
Read more →TLXTelix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
Telix has partnered with Subtle Medical to integrate AI-driven SubtlePET™ software with its Illuccix® product for enhanced PET imaging. The collaboration aims to reduce scan times by up to 75%, improving patient comfort and workflow efficiency. This partnership will initially focus on prostate cancer imaging in the U.S. and aims to expand to other PET tracers pending regulatory approval.
Read more →TLXTelix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix® Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle...
Telix Pharmaceuticals has partnered with Subtle Medical to utilize the AI-enabled SubtlePET™ software for enhancing PET imaging with their product, Illuccix®. This collaboration aims to streamline imaging procedures, significantly reducing scan times by up to 75% without compromising image quality. The technology is expected to improve patient experiences by minimizing wait times and discomfort. Launching in the U.S., the partnership is set to expand to other Telix PET-tracers pending regulatory approval.
Read more →TLXFDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix has announced that the FDA has accepted the New Drug Application for TLX101-CDx (Pixclara), a brain cancer imaging agent. The application has been granted priority review, with a PDUFA goal date set for April 26, 2025. Pixclara aims to improve the diagnosis and management of gliomas, addressing a significant unmet medical need in the U.S. market.
Read more →TLXTelix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
Telix is spinning off Rhine Pharma to improve access to innovative radiopharmaceuticals for cancer imaging and treatment. The new entity will focus on developing RHN001, a theranostic compound, in a Phase I/IIa clinical study targeting advanced prostate cancer. The use of generator-produced isotopes aims to simplify production and distribution, particularly in underserved regions.
Read more →TLXTelix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma[1], which has the mission of expanding...
Telix Pharmaceuticals has announced the spin-off of Rhine Pharma to enhance global access to innovative radiopharmaceuticals. This initiative follows a collaboration with Heidelberg University Hospital aimed at developing a PSMA-targeting small molecule for advanced prostate cancer treatment. The new entity plans to leverage generator-produced isotopes, technetium-99m and rhenium-188, which facilitate imaging and therapy while addressing manufacturing complexities. Rhine Pharma is now advancing its therapy through a Phase I/IIa clinical trial aimed at increasing access to cancer imaging and treatment.
Read more →TLXTelix Files Form 20-F Registration Statement for Nasdaq ADS
Telix Pharmaceuticals has filed a Form 20-F registration statement with the SEC for a proposed listing of American Depository Shares (ADS) on the Nasdaq. This initiative aims to provide easier access to Telix shares in the U.S. market and to attract global investors. The company plans to retain its primary listing on the Australian Securities Exchange while establishing the Nasdaq listing. However, the company has stated that it will not raise capital or issue new shares as part of this move, and the timing for initiating trading on Nasdaq remains uncertain.
Read more →TLXTelix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
Telix Pharmaceuticals Limited (ASX: TLX) reported a strong business update for Q3 2024, with unaudited revenue surpassing AU$200 million, reflecting substantial growth primarily driven by its prostate cancer imaging product, Illuccix. The company reaffirmed its revenue guidance for the year at US$490 million to US$510 million, projecting a significant increase compared to 2023. Additionally, Telix is advancing its clinical development programs and announced the acquisition of RLS (USA) Inc for US$230 million to bolster its manufacturing capabilities in North America. Although operational expenditures for R&D are expected to rise, the company remains optimistic about its strategic initiatives and market position.
Read more →TLXTelix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Telix will present thirteen abstracts at the upcoming EANM congress, highlighting its theranostic development and medical technologies. The presentations will cover various cancer therapies and imaging techniques, including real-world clinical experiences. The company aims to engage with delegates and promote collaboration in the field. Additionally, Telix supports the EANM Young Investigator Award to foster talent in radiopharmaceuticals.
Read more →TLXTelix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thirteen abstract presentations featuring the Company's ongoing...
Telix Pharmaceuticals Limited (ASX: TLX) has announced that it will present thirteen abstracts at the upcoming Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg from October 19 to 23, 2024. The presentations will cover various aspects of Telix's theranostic pipeline, including therapies for kidney and brain cancers, as well as bone marrow conditioning. This event represents a significant opportunity for Telix to highlight its innovative research in front of global nuclear medicine professionals.
Read more →TLXAustralian TGA Approves Additional Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
The Australian Therapeutic Goods Administration has approved Telix's Illuccix for selecting patients for PSMA-targeted radionuclide therapy. This approval expands Illuccix's clinical utility, allowing it to identify patients with metastatic prostate cancer for treatment with Pluvicto. The decision is expected to improve access to effective therapies for prostate cancer patients in Australia.
Read more →TLXHealth Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
Health Canada has approved the expanded use of Illuccix for selecting patients with progressive metastatic castration-resistant prostate cancer for PSMA-targeted therapy. This label expansion allows doctors to utilize Illuccix in conjunction with lutetium (177Lu) vipivotide tetraxetan, enhancing patient management. The approval reflects Telix's commitment to improving cancer care in Canada.
Read more →TLXFirst Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
Telix has initiated the Phase II CA-NINE trial, dosing its first patient with TLX250-CDx, a PET agent aimed at detecting recurrent clear cell renal cell carcinoma (ccRCC) after surgery. This trial, led by UCLA's Professor Brian Shuch, compares TLX250-CDx PET/CT imaging to conventional methods in 91 patients. The trial aims to enhance diagnostic accuracy for metastatic ccRCC and potentially expand the use of TLX250-CDx.
Read more →TLXTelix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
Telix Pharmaceuticals has announced its acquisition of RLS (USA) Inc., a leading radiopharmacy network, to enhance its manufacturing and distribution capabilities in North America. This acquisition will allow Telix to leverage RLS's extensive network of licensed radiopharmacies to improve access to radiopharmaceuticals across the U.S. The transaction, valued at approximately $230 million with potential additional payments, aligns with Telix's strategy of vertical integration in its supply chain. The acquisition is anticipated to close early in the first quarter of 2025 and is expected to support Telix's clinical and commercial product delivery.
Read more →TLXTelix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix
Telix Pharmaceuticals has appointed Cardinal Health as the commercial distributor for its kidney cancer imaging agent, Zircaix, in the United States, pending regulatory approval. This partnership is anticipated to enhance patient access to Zircaix by utilizing Cardinal Health's extensive distribution network. Zircaix has demonstrated strong clinical results with high accuracy in distinguishing renal masses, indicating its potential as a valuable diagnostic tool. The distribution agreement aims to pave the way for a successful rollout of this investigational radiopharmaceutical across various U.S. locations.
Read more →TLX‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
Telix's Phase III ZIRCON trial results reveal that TLX250-CDx is highly effective in detecting clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses. The study, published in The Lancet Oncology, highlights the agent's favorable safety profile and its potential to change clinical practices. If approved by the FDA, it will be the first targeted PET agent for kidney cancer in the U.S.
Read more →TLX'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been...
Telix Pharmaceuticals announced the publication of primary results from its Phase III ZIRCON trial in The Lancet Oncology, demonstrating that TLX250-CDx is a highly accurate method for detecting clear cell renal cell carcinoma in patients with indeterminate renal masses. The trial involved 300 patients and concluded that TLX250-CDx offers a favourable safety profile and the potential to change clinical practice. This investigational PET agent targets carbonic anhydrase IX, which is highly expressed in ccRCC, and could improve diagnostic accuracy over current imaging techniques.
Read more →TLXIPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
Telix's IPAX-1 Phase I study on TLX101 for recurrent glioblastoma has been published in Neuro-Oncology Advances. The study indicates a favorable safety profile and promising early efficacy, with a median overall survival of 13 months. Researchers advocate for further investigation into TLX101 combined with external beam radiation therapy as a potential first-line treatment.
Read more →TLXIPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in...
Telix Pharmaceuticals Limited has announced the publication of their IPAX-1 Phase I study in Neuro-Oncology Advances, showcasing the safety and tolerability of TLX101 therapy for recurrent glioblastoma. The study revealed encouraging preliminary efficacy with a median overall survival of 13 months post-treatment. The results indicate that TLX101, when used alongside external beam radiation therapy, may represent a new therapeutic option for this aggressive form of brain cancer. Further studies are planned to advance TLX101 as a potential first-line treatment.
Read more →TLXTelix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix has submitted a New Drug Application (NDA) for TLX101-CDx, an investigational PET imaging agent for glioma characterization. The FDA has granted it Orphan Drug and Fast Track designations, highlighting its potential to address significant medical needs. This submission is a crucial step towards improving neuro-oncology imaging and may lead to commercial availability in 2025, pending FDA approval.
Read more →TLXTelix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States...
Telix Pharmaceuticals Limited has submitted a New Drug Application (NDA) to the U.S. FDA for TLX101-CDx, an imaging agent aimed at characterizing glioma in patients. This investigational agent has received Orphan Drug and Fast Track designations, which expedite its review process due to the significant unmet medical needs associated with brain cancer. TLX101-CDx targets specific proteins, positioning it as a potential companion diagnostic for the investigational glioblastoma therapy TLX101. This development highlights Telix's commitment to addressing gaps in the diagnosis and treatment of brain cancer.
Read more →TLXTelix Announces Reorganisation to Deliver on Strategic Priorities
Telix has announced a reorganisation to align its operations into four business units, focusing on its commitment to precision oncology. The new structure includes leadership changes aimed at optimising the development and commercialisation of theranostic radiopharmaceuticals. The company is experiencing growth in its therapeutics business, with several candidates advancing to pivotal clinical trials.
Read more →TLXTelix Announces Reorganisation to Deliver on Strategic Priorities Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to...
Telix Pharmaceuticals has announced an internal reorganization to enhance its strategic priorities. This includes new leadership appointments aimed at optimizing the development and commercialization of theranostic radiopharmaceuticals. The company continues to focus on addressing unmet medical needs in oncology and rare diseases, supported by the recent approvals of its lead imaging product, Illuccix®. The changes reflect Telix's commitment to improving its operational efficiency and market potential.
Read more →TLXTelix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
Telix Pharmaceuticals Limited reported a strong financial performance for the first half of 2024, with total group revenue increasing by 65% to $364 million, largely driven by sales of its prostate cancer imaging agent, Illuccix. The company also shifted from a loss of $14.3 million in the previous year to a profit of $29.7 million. Telix affirmed its full-year revenue guidance of up to $510 million, highlighting its operational advancements and ongoing product developments in precision medicine. Additionally, the company successfully raised $650 million through a convertible bond offering, enhancing its position for future growth and clinical developments.
Read more →TLXTelix Half-Year Results 2024 Investor Webcast Notification
Telix Pharmaceuticals will announce its financial results for the half-year ending June 30, 2024, on August 22, 2024. An investor webcast is scheduled for August 23, 2024, at 9:00 AM AEST. This event will provide stakeholders an opportunity to engage with the company's financial performance.
Read more →TLXExpanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
Telix has launched an expanded access program for TLX101-CDx, an investigational PET imaging agent for glioma, following FDA approval. This program aims to enhance patient access to this important diagnostic tool, which is expected to file for NDA in Q3 2024. Experts believe TLX101-CDx could significantly improve glioma management in the U.S.
Read more →TLXTelix has released an update to its Modern Slavery Statement
Telix has updated its Modern Slavery Statement, reaffirming its commitment to human rights and zero tolerance for modern slavery. The statement outlines the company's ongoing efforts to combat exploitation, including forced labor and human trafficking. Telix emphasizes ethical standards and encourages employees and partners to uphold these values.
Read more →TLXFDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
Telix has announced that the FDA has accepted its New Drug Application for TLX007-CDx, a new cold kit for PSMA-PET imaging in prostate cancer. The PDUFA goal date is set for March 24, 2025. This innovative kit aims to improve patient access to imaging services, particularly for underserved communities. The company is committed to enhancing equity in healthcare access for prostate cancer patients.
Read more →TLXTelix Successfully Prices A$650 Million Convertible Bonds
Telix has successfully priced A$650 million in convertible bonds with a 2.375% interest rate, due in 2029. The bonds will support the company's clinical development programs and provide financial flexibility for potential M&A opportunities. The offering received strong investor support, reflecting confidence in Telix's strategic direction.
Read more →TLXTelix Announces A$600 Million Convertible Bonds Offering
Telix has announced a A$600 million offering of convertible bonds due in 2029. This move aims to enhance financial flexibility and support the company's growth strategies, including investments in clinical development programs for its theranostic portfolio. The offering is expected to fund pivotal trials and explore potential M&A opportunities.
Read more →TLXTelix Announces A$600 Million Convertible Bonds Offering Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering of A$600 million of convertible notes due 2029...
Telix Pharmaceuticals Limited has launched an offering of A$600 million in convertible bonds due in 2029 to support its growth strategy. The capital raised will facilitate key investments in the company's clinical pipeline, enabling the acceleration of pivotal trials and label-expansion studies for its theranostic portfolio. The offering is anticipated to enhance financial flexibility and potentially create opportunities for strategic mergers and acquisitions. Managing Director Dr. Christian Behrenbruch emphasized the strong commercial performance that underpins this funding initiative.
Read more →TLXTelix Successfully Prices A$650 Million Convertible Bonds Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully priced A$650 million 2.375...
Telix Pharmaceuticals Limited has successfully priced A$650 million in convertible bonds with an interest rate of 2.375%, due in 2029. The bonds received robust interest from global investors, highlighting market confidence in the Company. The proceeds are earmarked for vital investments aimed at expediting clinical development programs and potentially pursuing strategic M&A opportunities. The conversion price sets a premium of 32.5% above the reference share price, reflecting favorable market conditions.
Read more →TLXQ2 2024 Revenue and Business Highlights, Guidance Upgrade
Telix reported strong financial performance for Q2 2024, with revenues reaching approximately US$124M, a 55% increase from the same quarter last year. The company has upgraded its FY2024 revenue guidance to between US$490M and US$510M. Operationally, Telix is making progress in its theranostic pipeline and welcomes proposed regulatory changes that could enhance payment structures for its products. However, the company advises caution regarding the reliability of its guidance due to potential risks.
Read more →TLXTelix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
Telix Pharmaceuticals Limited has welcomed the Centers for Medicare & Medicaid Services' (CMS) proposed changes to improve payment for specialized diagnostic radiopharmaceuticals under the Hospital Outpatient Prospective Payment System (OPPS). The proposal allows for separate payments for certain diagnostic radiopharmaceuticals, including Telix's Illuccix®, thereby ensuring continued access for Medicare patients. The changes are aimed at improving payment accuracy and will apply to new products developed by Telix once approved. A 60-day comment period for the proposal ends on September 9, 2024.
Read more →TLXTelix Elects to Withdraw from Proposed U.S. Listing
Telix has decided to withdraw its proposed IPO in the U.S. due to unfavorable market conditions. The company emphasized that the decision aligns with its responsibility to existing shareholders. Despite this setback, Telix has achieved significant milestones, including positive data readouts and share price appreciation. The company remains focused on its strategic objectives and growth in the U.S. market.
Read more →TLXTelix Announces Launch of Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited has announced the launch of its initial public offering (IPO) in the United States, aiming for gross proceeds of $200 million through the sale of 17 million American Depositary Shares (ADSs). The company intends to list its ADSs on the Nasdaq Global Market under the ticker symbol TLX while continuing to trade on the Australian Securities Exchange. Jefferies, Morgan Stanley, Truist Securities, and William Blair are acting as joint book-running managers for the offering. Telix's strategic move marks its entry into the U.S. market, highlighting its focus on developing treatments in oncology and other therapeutic areas.
Read more →TLXTelix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
Telix has completed the Biologics License Application (BLA) submission for TLX250-CDx, a radiodiagnostic agent for clear cell renal cell carcinoma (ccRCC). The submission is based on the successful Phase III ZIRCON study, which demonstrated high sensitivity and specificity for detecting ccRCC. Telix has also requested a Priority Review from the FDA, which could expedite the approval process. If approved, TLX250-CDx will be the first targeted imaging agent for kidney cancer available in the U.S.
Read more →TLXTelix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application...
Telix Pharmaceuticals has completed its Biologics License Application (BLA) submission for TLX250-CDx, an investigational radiodiagnostic agent aimed at imaging kidney cancer. The application follows successful results from the Phase III ZIRCON study, which demonstrated substantial sensitivity and specificity in detecting clear cell renal cell carcinoma. The company has requested Priority Review from the FDA, which could expedite the approval process. This development marks a potential advancement in the available diagnostic tools for renal cancer in the U.S.
Read more →TLXTelix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
Telix has announced positive results from the ProstACT SELECT trial of TLX591, a radiolabeled therapy for metastatic castrate-resistant prostate cancer. The trial reported a median radiographic progression-free survival (rPFS) of 8.8 months in a sample of 23 patients. This outcome supports further development of TLX591, particularly in earlier treatment settings where there is significant unmet need.
Read more →TLXTelix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive data from the ProstACT SELECT trial ( SELECT ) of...
Telix Pharmaceuticals announced promising data from the ProstACT SELECT trial of TLX591, a radio antibody-drug conjugate for treating metastatic castrate-resistant prostate cancer. The trial reported a median radiographic progression-free survival (rPFS) of 8.8 months for patients, suggesting potential effectiveness in a population with significant unmet needs. The therapy is being evaluated in the upcoming Phase III ProstACT GLOBAL trial, aiming to advance treatment options for early-stage mCRPC patients. Notably, TLX591's dosing regimen minimizes cumulative radiation exposure compared to existing therapies.
Read more →TLXTelix Submits NDA for New Prostate Cancer Imaging Agent
Telix Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. FDA for its innovative PSMA-PET imaging agent, TLX007-CDx. This new cold kit aims to improve prostate cancer diagnosis by providing enhanced accessibility and production flexibility compared to current options. The company emphasizes that this product may help address disparities in access to prostate cancer imaging among underserved populations, such as African Americans and Veterans, who are disproportionately affected by the disease. If approved, TLX007-CDx is expected to significantly impact patient care and outcomes.
Read more →TLXTelix Highlights ProstACT GLOBAL and STARLITE-1 Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2024
Telix Pharmaceuticals will present two significant studies at the 2024 ASCO Annual Meeting. The ProstACT GLOBAL study evaluates TLX591 in metastatic castrate-resistant prostate cancer, while the STARLITE-1 trial investigates TLX250 in advanced clear cell renal cell carcinoma. Both studies aim to enhance treatment options for these aggressive cancers.
Read more →TLXTelix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Telix has completed the CUPID 1 Phase I study of TLX592, a targeted alpha therapy for advanced prostate cancer. The study demonstrated promising safety and pharmacokinetics, with no serious adverse events. Telix plans to move forward with a Phase I/II therapeutic study later in 2024, pending regulatory approval.
Read more →TLXTelix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer....
Telix Pharmaceuticals announced the successful completion of the CUPID study, a first-in-human Phase I trial of TLX592, a targeted alpha therapy for advanced prostate cancer. The study demonstrated encouraging results, including favorable blood kinetics and safety profiles without severe adverse events. Telix plans to advance TLX592 into a therapeutic Phase I/II study in the second half of 2024, pending regulatory approval. This development enhances Telix's portfolio focused on PSMA-targeting prostate cancer therapies.
Read more →TLXTelix Files Registration Statement for Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited has officially submitted a registration statement with the U.S. SEC for a proposed initial public offering of its American Depository Shares. The company intends to list on the Nasdaq under the ticker 'TLX', though the specifics regarding the number of shares and pricing are yet to be finalized. The move aims to bolster Telix's capital resources and enhance its market presence, subject to prevailing market conditions. Joint book-running managers for the offering include Jefferies and Morgan Stanley among others.
Read more →TLXTelix Announces Abstract Presentations at BNMS Annual Spring Meeting
Telix Pharmaceuticals has announced three abstract presentations at the BNMS Annual Spring Meeting in Belfast. The presentations will showcase their Phase III ZIRCON Study of TLX250-CDx for clear cell renal cell carcinoma and TLX66, a bone marrow conditioning therapy. Notable sessions include cutting-edge research and physics dosimetry discussions.
Read more →TLXTelix and Cardinal Health Complete Global Clinical Supply Agreement for Actinium-225 for Targeted Alpha Therapy Pipeline Development
Telix has entered a global clinical supply agreement with Cardinal Health for actinium-225, a key radioisotope in the development of its targeted alpha therapy pipeline. This partnership aims to enhance the availability of Ac-225, crucial for treating various cancers. Telix's ongoing research includes therapies for prostate cancer and soft tissue sarcoma, positioning the company at the forefront of innovative cancer treatments.
Read more →TLXTelix Completes Acquisition of QSAM Biosciences and Its Bone Cancer Targeting Platform
Telix has completed the acquisition of QSAM Biosciences, gaining access to the investigational drug Samarium-153-DOTMP, which targets bone cancer. This acquisition aims to enhance Telix's prostate cancer therapy offerings and address unmet needs in pain management for patients with bone metastases. The technology is expected to provide a continuum of care from diagnosis to palliative treatment.
Read more →TLXFirst Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix Pharmaceuticals has announced the first patient dosing in Austria for TLX250-CDx, a PET imaging agent targeting clear cell renal cell carcinoma. This follows the successful Phase III ZIRCON study, which met all endpoints. The program allows individual patient access to this innovative diagnostic tool, addressing an urgent need for non-invasive kidney cancer detection.
Read more →TLXTelix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591
Telix Pharmaceuticals will present five oral abstracts at the AUA Annual Meeting, highlighting its late-stage theranostic programs in urology. Key presentations include the ProstACT GLOBAL Phase III study of TLX591, a novel therapy for prostate cancer, and discussions on the role of PSMA imaging in cancer management. The company will also host thought leadership sessions on kidney cancer detection and management.
Read more →TLXFirst Patient Dosed in Special Access Scheme in Australia for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix has announced the first patient dosing of TLX250-CDx under Australia's Special Access Scheme. This imaging agent aims to enhance diagnosis and treatment planning for clear cell renal cell carcinoma without invasive procedures. The patient was treated at a leading cancer center, and Telix is also pursuing regulatory approval in the U.S. and other regions.
Read more →TLXTelix at ANZSNM Annual Scientific Meeting 2024
Telix Pharmaceuticals will present five oral abstracts at the ANZSNM ASM 2024 in Christchurch, focusing on their theranostic programs for prostate and kidney cancers. The presentations include data on TLX591 and Illuccix®, among others. Additionally, Telix will host a Breakfast Session and support a Nurses Workshop, emphasizing innovations in theranostics.
Read more →TLXNotice of Annual General Meeting 2024
Telix Pharmaceuticals Limited has announced its Annual General Meeting (AGM) scheduled for May 22, 2024. The meeting will take place at The Wesley Conference Centre in Sydney and will be hybrid, allowing shareholders to participate in person or via webcast. This setup aims to enhance shareholder engagement and participation.
Read more →TLXQ1 2024 Revenue and Business Update
Telix reported a strong Q1 2024 with total revenue of US$114.9M, marking an 18% increase from the previous quarter. The growth was primarily driven by sales of its prostate cancer imaging product, Illuccix. The company also reaffirmed its full-year revenue guidance of US$445M to $465M, alongside a significant increase in R&D investment. Recent acquisitions are expected to enhance Telix's manufacturing capabilities and support its oncology pipeline.
Read more →TLXTLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
Telix has received FDA Fast Track designation for TLX101-CDx, an investigational glioma imaging product. This designation will expedite the review process as Telix prepares its New Drug Application for both adult and pediatric patients. The collaboration with UCSF aims to enhance the product's clinical utility, while PharmaLogic will handle manufacturing and distribution upon regulatory approval.
Read more →TLXTLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)
Telix has announced that TLX250-CDx (Zircaix®) has been included in the updated European Association of Urology (EAU) guidelines as an emerging technology for renal cell carcinoma (RCC). This recognition is based on positive results from the Phase III ZIRCON trial, which showed a high positive-predictive value for detecting clear cell RCC. The guidelines aim to enhance clinical practice standards in urologic oncology across Europe.
Read more →TLXTelix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform
Telix has completed the acquisition of ARTMS Inc., a company specializing in cyclotron-based isotope production technology. This acquisition is expected to enhance Telix's supply chain and regulatory control over key isotopes, while also facilitating broader patient access to therapeutic and diagnostic radiopharmaceuticals. The deal includes an upfront payment of $57.5 million and potential future earn-out payments based on clinical or commercial milestones.
Read more →TLXTelix Completes Acquisition of IsoTherapeutics
Telix has completed the acquisition of IsoTherapeutics, a company specializing in radiochemistry and bioconjugation. This acquisition enhances Telix's development capabilities and expands its manufacturing footprint in the U.S. The transaction involves an upfront payment of $8.1 million, with additional performance-related milestone payments possible. The acquisition is seen as a significant milestone for Telix's vertical integration strategy.
Read more →TLXTelix GM 2024
Telix held its General Meeting on April 5, 2024, at The Wesley Conference Centre in Sydney, Australia, and online. The event included addresses from the Chairman and CEO, along with presentations. Additional resources such as the Notice of Meeting and Proxy Form were provided for attendees.
Read more →TLXTelix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU
Telix Pharmaceuticals will present its late-stage theranostic programs at the upcoming EAU Congress in Paris. The presentations will include updates on the Phase III ProstACT GLOBAL study for TLX591 in metastatic castration-resistant prostate cancer and the Phase II STARBURST study for TLX250-CDx. These studies aim to enhance the understanding of these therapies and their potential applications in cancer treatment.
Read more →TLXWorld First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
Lightpoint Surgical Limited has announced the successful world-first use of its SENSEI® gamma probe in a bladder cancer sentinel lymph node procedure at Hospital del Mar in Barcelona, Spain. The device, designed for robotic-assisted surgery, allows for more precise detection of cancerous lymph nodes while minimizing damage to surrounding tissue. This milestone highlights the potential for SENSEI® in various urologic malignancies.
Read more →TLXFirst Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix has initiated its named patient program in Italy for TLX250-CDx, a PET imaging agent for clear cell renal cell carcinoma. The first patient was dosed at IRCCS Ospedale San Raffaele, following successful results from the Phase III ZIRCON study. This program aims to provide non-invasive diagnostic options for patients with ccRCC, addressing significant unmet medical needs.
Read more →TLXFirst Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in its named patient program in...
Telix Pharmaceuticals Limited has announced the dosing of the first patient in its named patient program for TLX250-CDx in Italy, which targets clear cell renal cell carcinoma (ccRCC). This program allows physicians in Italy to access the investigational imaging agent outside clinical trials. The announcement follows the completion of the successful Phase III ZIRCON study that confirmed TLX250-CDx's effectiveness. Italy becomes the third country to implement Telix's expanded access program, joining the Netherlands and the United States.
Read more →TLXQDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
Telix has partnered with ABX-CRO and Quantinm AB to commercialize the QDOSE® dosimetry software platform. This collaboration aims to enhance personalized treatment regimens in radiopharmaceutical therapy, optimizing patient outcomes while minimizing impacts on healthy organs. The QDOSE® platform is FDA cleared and CE marked, supporting various imaging techniques for dosimetry calculations.
Read more →TLXQDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® ...
Telix Pharmaceuticals Limited has announced a commercial partnership with ABX-CRO for the QDOSE® dosimetry software platform. This platform aims to provide personalized dosimetry for radiopharmaceutical therapies, potentially improving treatment outcomes while minimizing adverse effects on healthy organs. QDOSE® has already received FDA clearance and CE marking, indicating its readiness for clinical use in both the US and EU. The partnership reflects a strategic move to advance personalized cancer treatment through innovative technologies in dosimetry analysis.
Read more →TLXAppointment of Dr Darren Patti to Group Chief Operating Officer
Telix has appointed Dr. Darren Patti as Group Chief Operating Officer, effective March 11, 2024. Dr. Patti has been with Telix since March 2021, leading U.S. operations and overseeing successful product launches. His extensive experience in radiopharmacy and operational management positions him well to drive Telix's global expansion and manufacturing capabilities.
Read more →TLXAppointment of Dr Darren Patti to Group Chief Operating Officer Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating...
Telix Pharmaceuticals Limited has announced the appointment of Dr. Darren Patti as Group Chief Operating Officer, effective March 11, 2024. Dr. Patti, who previously served as COO and General Manager for Telix's U.S. operations since March 2021, played a significant role in successful product launches including Illuccix in the U.S. and Canada. With a strong background in the biopharmaceutical field, Dr. Patti holds a Doctor of Pharmacy degree and has previously worked at Sofie Biosciences. His new role is expected to enhance Telix's operations in the biopharmaceutical landscape.
Read more →TLXNotice of General Meeting
Telix has announced a general meeting for shareholders scheduled for April 5, 2024, at The Wesley Conference Centre in Sydney. The meeting will also be available online, allowing broader participation. Shareholders can access the full Notice of Meeting, Proxy Form, and Online Guide through the provided link.
Read more →TLXTelix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
Telix has announced its acquisition of ARTMS, Inc., a company specializing in advanced cyclotron-based isotope production technology. This acquisition aims to enhance Telix's supply chain and manufacturing capabilities while providing a greater level of control over diagnostic isotopes. The integration of ARTMS's technology is expected to improve production efficiency and support the development of new therapeutic isotopes.
Read more →TLXTelix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production...
Telix Pharmaceuticals Limited has announced its agreement to acquire ARTMS, Inc., a company specializing in advanced radioisotope production technology, including its QUANTM Irradiation System. This acquisition is expected to enhance Telix's supply chain integration and ensure the efficient production of critical medical isotopes. The deal includes ARTMS's production facility in Burnaby, BC, and aims to improve Telix's financial performance through increased revenue and better margins. Regulatory approvals and customary conditions must still be met for the transaction to close.
Read more →TLXTelix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
Telix has announced the acquisition of IsoTherapeutics Group, a Texas-based radiopharmaceutical firm. This strategic move aims to enhance Telix's manufacturing and development capabilities, allowing for greater vertical integration. The acquisition will expand Telix's U.S. footprint and is expected to yield cost savings by bringing certain R&D activities in-house. The deal is subject to regulatory approvals.
Read more →TLXTelix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC...
Telix Pharmaceuticals Limited (ASX: TLX) has announced its agreement to acquire IsoTherapeutics Group, LLC, a radiopharmaceutical development company based in Texas. This acquisition is part of Telix's strategy to enhance its in-house drug development capabilities and reduce costs and timelines for technical milestones. It will also broaden the company's manufacturing presence in the U.S. and improve its overall operational capacity in radiochemistry. Upon closing, IsoTherapeutics will continue to serve its existing customer base while integrating with Telix's operations.
Read more →TLXTelix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
Telix reported its financial results for 2023, marking its first profit while investing heavily in late-stage assets. The company anticipates a revenue increase of 35-40% for 2024, driven by sales of Illuccix® and potential new products. The CEO emphasized the importance of their theranostic pipeline and vertical integration for future growth.
Read more →TLXTelix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures...
Telix Pharmaceuticals Limited (ASX: TLX) announced its financial results for the year ending December 31, 2023, marking its first profit while significantly investing in late-stage assets and commercial infrastructure. The company expects revenue growth of 35-40% for 2024, driven by its product Illuccix® and potential new offerings, Zircaix™ and Pixclara™. Telix is concentrating on expanding its theranostic pipeline and enhancing its manufacturing capabilities. Despite the optimistic outlook, no specific risks or negative events were highlighted in the announcement.
Read more →TLXTelix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
Telix Pharmaceuticals has announced its agreement to acquire QSAM Biosciences, which includes the acquisition of the investigational drug 153Sm-DOTMP aimed at treating bone cancer. This drug demonstrates potential for pain management in patients with metastatic bone disease and has received FDA designations that may facilitate faster market entry. The acquisition is seen as a strategic move to enhance Telix's existing portfolio in oncology. The deal entails an upfront payment and potential future payments contingent on achieving certain milestones, pending regulatory approvals.
Read more →TLXTelix Full Year Results 2023 Investor Webcast Notification
Telix Pharmaceuticals will announce its full year results for 2023 on February 22, 2024. An investor webcast is scheduled for February 23, 2024, allowing stakeholders to engage directly with the company. This event highlights Telix's commitment to transparency and investor relations.
Read more →TLXTelix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
Telix Pharmaceuticals Limited will present its theranostic programs at the ASCO GU 2024 symposium in San Francisco from January 25-27. Key presentations will include the ProstACT GLOBAL study, a Phase III trial on TLX591 for metastatic prostate cancer, alongside findings from the ProstACT SELECT study. The symposium will also feature the STARLITE-1 trial for TLX250 in renal cell carcinoma. This participation highlights Telix's ongoing commitment to advancements in cancer care.
Read more →TLXPresentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update
Telix is set to present at the 42nd Annual J.P. Morgan Healthcare Conference, providing an update on its Q4 2023 revenue, which reached $148.1M, marking an 11% increase from the previous quarter. The company also reported total revenue of $502.5M for FY 2023. CEO Dr. Christian Behrenbruch expressed optimism about the company's performance and pipeline advancements.
Read more →TLXTelix Announces Planned Registered Public Offering and Listing in the United States
Telix Pharmaceuticals announced plans for a potential initial public offering of American Depositary Shares in the United States, aiming for a listing on the Nasdaq Global Market. While the specific number of shares, pricing, and timing have yet to be determined, the company assures its ordinary shares will continue to be listed on the Australian Securities Exchange. This move may enhance Telix's visibility in the U.S. market, but there are inherent risks related to the success of the offering and market conditions that remain to be addressed.
Read more →TLXTelix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Telix Pharmaceuticals Limited, based in Melbourne, has announced that Dr. Christian Behrenbruch will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2024. The presentation is expected to highlight Telix's developments in diagnostic and therapeutic radiopharmaceuticals. Participants can register for a webcast of the event, which will also be available on demand afterward. This presentation aims to facilitate engagement with investors and stakeholders in the biopharmaceutical sector.
Read more →TLXAppointment of Dr David Cade to Group Chief Medical Officer
Telix has appointed Dr. David Cade as the new Group Chief Medical Officer, effective January 1, 2024. He succeeds Dr. Colin Hayward, who is stepping down to pursue other interests. Dr. Cade brings significant experience in oncology and has held various senior roles at Telix, including CEO of the Asia-Pacific business. His appointment is seen as a strategic move to enhance Telix's clinical programs.
Read more →TLXTelix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
Telix has submitted a Biologics License Application (BLA) for TLX250-CDx, a PET imaging agent for clear cell renal cell carcinoma, to the FDA. The submission includes a request for Priority Review under the Breakthrough Therapy designation, which allows for a rolling review process. If approved, TLX250-CDx will be the first targeted imaging agent for kidney cancer available in the U.S., addressing a significant unmet need.
Read more →TLXTelix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the...
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) for its imaging agent TLX250-CDx to the FDA for the diagnosis of clear cell renal cell carcinoma. This application follows the successful results of the global Phase III ZIRCON study. The FDA's Breakthrough Therapy designation allows a rolling review process and Telix has requested Priority Review to expedite the process. If approved, TLX250-CDx will be the first targeted radiopharmaceutical imaging agent for kidney cancer available in the U.S.
Read more →TLXFirst Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix’s Breakthrough Kidney Cancer Imaging Agent
Telix has initiated an expanded access program for TLX250-CDx, a PET imaging agent for clear cell renal cell carcinoma, with the first patient dosed in Austin, Texas. This program follows the successful Phase III ZIRCON study, which met all endpoints. The EAP aims to provide access to this investigational agent before full regulatory approval.
Read more →TLXFirst Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded ...
Telix Pharmaceuticals Limited announced that the first patient has been dosed in the U.S. Expanded Access Program for TLX250-CDx, a non-invasive imaging agent for clear cell renal cell carcinoma. The dosing took place at ARA Diagnostic Imaging following FDA approval to proceed with the program. This initiative aims to provide continued access to TLX250-CDx, addressing a significant unmet need as the company moves towards a Biologics License Application submission. The recent successful Phase III ZIRCON study demonstrated the potential of TLX250-CDx to become a new standard of care.
Read more →TLXPositive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
Telix has announced positive topline results from its Phase II OPALESCENCE study of TLX250-CDx in triple negative breast cancer (TNBC). The study showed effective CAIX-targeting PET imaging in metastatic patients, highlighting the potential of TLX250-CDx to detect aggressive lesions. The results will be presented at the 2023 SABCS, indicating a promising future for CAIX-targeted therapies.
Read more →TLXPositive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated...
Telix Pharmaceuticals Limited announced positive topline results from its Phase II OPALESCENCE study of TLX250-CDx for triple negative breast cancer. The trial demonstrated the successful targeting of carbonic anhydrase IX (CAIX) in metastatic patients, showing promise for improved diagnosis and staging. The results will be presented at the 2023 San Antonio Breast Cancer Symposium, highlighting the potential for TLX250-CDx to transition into therapeutic applications. This development addresses significant unmet medical needs in treating triple negative breast cancer, which currently has limited options available for patients.
Read more →TLXFirst Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix has initiated a named patient program in the Netherlands for TLX250-CDx, its PET imaging agent for clear cell renal cell carcinoma (ccRCC). The first patient was dosed at Radboud University Medical Centre. This program follows the successful Phase III ZIRCON study, which demonstrated the agent's effectiveness in detecting ccRCC. The program allows physicians to access TLX250-CDx for non-invasive imaging of renal masses.
Read more →TLXFirst Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access)...
Telix Pharmaceuticals has announced that the first patient has been dosed in the named patient (early access) program for its imaging agent TLX250-CDx, aimed at helping in the detection of clear cell renal cell carcinoma (ccRCC). This is particularly significant given the challenges posed by conventional methods in early disease detection. The initiative follows the successful Phase III ZIRCON study, which validated TLX250-CDx's effectiveness. Physicians can now access this innovative imaging option in the Netherlands, marking a notable advancement in oncology diagnosis and management.
Read more →TLXPhase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
Telix has announced that the Phase II OPALESCENCE study of TLX250-CDx will be presented at the 2023 San Antonio Breast Cancer Symposium. The study aims to evaluate CAIX-targeted PET imaging for diagnosing and staging triple-negative breast cancer. Dr. Caroline Rousseau will present the top-line results on December 6, highlighting the potential of CAIX as a therapeutic target.
Read more →TLXPhase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) ...
Telix Pharmaceuticals Limited has announced that the results of the Phase II OPALESCENCE study, which investigates TLX250-CDx in patients with triple-negative breast cancer, will be presented at the upcoming 2023 San Antonio Breast Cancer Symposium. The study focuses on the utilization of CAIX-targeted imaging with positron emission tomography (PET) for diagnosis and staging. Principal Investigator Dr. Caroline Rousseau will deliver the key findings on December 6. The research aims to enhance understanding of CAIX as a potential therapeutic target.
Read more →TLXExpert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591
An expert forum moderated by Dr. Colin Hayward discussed the advancements in PSMA-targeted radiopharmaceuticals, particularly focusing on Telix's investigational drug TLX591. The forum highlighted the ProstACT GLOBAL study and recent findings from the ProstACT SELECT study, showcasing the potential benefits of this antibody-based therapy. Key opinion leaders in prostate cancer provided insights into the evolving treatment landscape.
Read more →TLXTelix to Host Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591
Telix will host an investor webcast on November 21, 2023, focusing on PSMA-targeted radiopharmaceuticals, particularly its investigational drug TLX591. The event will feature discussions led by key opinion leaders in prostate cancer treatment, highlighting the ProstACT study designs and recent findings. Participants can register online, and a recording will be available post-event.
Read more →TLXTelix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
Telix has signed a conditional Term Sheet to acquire QSAM Biosciences and its lead therapy candidate, CycloSam®. This acquisition aims to enhance Telix's capabilities in treating bone cancer and improve patient care. CycloSam® has received FDA designations that may expedite its market entry, addressing significant needs in metastatic disease management.
Read more →TLXTelix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery
Telix and Mauna Kea Technologies have announced a €6.0 million investment to expand their IRiS Alliance, focusing on developing hybrid pharmaceutical-device products for urologic oncology surgery. This collaboration aims to integrate Telix's cancer-targeting agents with Mauna Kea's Cellvizio platform to enhance surgical imaging techniques. The partnership is expected to improve surgical planning and real-time cancer detection.
Read more →TLXTelix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam® Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. ...
Telix Pharmaceuticals has announced its intention to acquire QSAM Biosciences and its lead asset CycloSam®, aimed at improving treatment for metastatic bone cancer. This acquisition, contingent on customary approvals, is positioned to enhance Telix's pipeline, particularly in the context of prostate cancer and sarcoma. CycloSam® has received orphan designation from the FDA, which could expedite its market entry. The acquisition terms include an upfront payment and potential milestone payments based on performance.
Read more →TLXTelix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Paris-based Mauna Kea Technologies (Euronext Growth: ALMKT, Mauna Kea), today...
Telix Pharmaceuticals has announced an expansion of its collaboration with Mauna Kea Technologies through a €6.0 million investment aimed at developing hybrid pharmaceutical-device products, particularly in urologic oncology surgery. This investment will enhance the capabilities of Telix’s cancer-targeting agents when used alongside Mauna Kea’s FDA-approved Cellvizio imaging platform. With this move, Telix secures a 19.33% ownership stake in Mauna Kea, facilitating further integration of advanced imaging techniques for minimally invasive surgical procedures. The collaboration aims to improve surgical planning and outcomes for patients with urological cancers.
Read more →TLXFirst Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
Telix has announced the first patient dosing in its Phase III ProstACT GLOBAL study for TLX591, an investigational therapy targeting PSMA in metastatic castrate-resistant prostate cancer. This study aims to evaluate TLX591's effectiveness alongside standard care versus standard care alone. Previous studies have shown promising safety and efficacy, with a target enrollment of approximately 400 patients.
Read more →TLXFirst Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III...
Telix Pharmaceuticals Limited has announced the dosing of the first patient in the Phase III ProstACT GLOBAL study for TLX591, an investigational radio-antibody drug conjugate aimed at treating metastatic castrate-resistant prostate cancer. This study is notable as it evaluates TLX591 alongside standard of care therapies, potentially enhancing treatment outcomes for patients. Prior studies have indicated a promising safety profile and patient survival benefits associated with TLX591. The ongoing international expansion of the study is contingent on obtaining necessary regulatory approvals.
Read more →TLXTelix to Present at Jefferies London Healthcare Conference 2023
Telix Pharmaceuticals announced that Dr. Christian Behrenbruch, the Managing Director and Group CEO, will present at the Jefferies London Healthcare Conference 2023. The presentation is scheduled for November 15, 2023, from 4:00 to 4:30 PM GMT. A webcast of the event will be available for registration and on-demand viewing afterward.
Read more →TLXTelix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
Telix has signed an exclusive distribution agreement with Wiik Pharma for its investigational prostate cancer imaging agent, Illuccix, in the Nordic region. The agreement allows Wiik Pharma to distribute Illuccix in Denmark, Finland, Norway, and Sweden for three years following national approval. Both companies express optimism about improving patient care through this partnership.
Read more →TLXTelix to Present at Jefferies London Healthcare Conference 2023 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be...
Telix Pharmaceuticals Limited announced that Dr. Christian Behrenbruch, Managing Director and Group CEO, will present at the Jefferies London Healthcare Conference 2023 on November 15. The event aims to showcase the company's developments in diagnostic and therapeutic radiopharmaceuticals. Following the live presentation, attendees will have the option to access the webcast on demand. This platform provides Telix with a significant opportunity to engage with potential investors and stakeholders on their latest innovations.
Read more →TLXTelix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS...
Telix Pharmaceuticals has signed an exclusive distribution agreement with WIIK Pharma for its investigational prostate cancer imaging agent, Illuccix, in the Nordic region. This partnership aims to address the growing need for advanced diagnostics in prostate cancer, especially given the high incidence rates in Denmark, Finland, Norway, and Sweden. The agreement establishes Wiik Pharma as the exclusive distributor in these countries for three years after national approval, highlighting the significance of this collaboration in improving patient care in the region.
Read more →TLXTelix Completes Acquisition of Lightpoint Medical
Telix has completed the acquisition of Lightpoint Medical, enhancing its capabilities in precision-guided robotic cancer surgery. The acquisition focuses on integrating Lightpoint's SENSEI technology with Telix's existing prostate cancer programs. The deal includes an upfront payment of $20 million and potential earn-out payments based on future milestones.
Read more →TLXProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
Telix Pharmaceuticals announced positive interim results from the Phase I ProstACT SELECT study of TLX591, a therapy for metastatic castration-resistant prostate cancer. The study confirmed the safety and tolerability of TLX591, demonstrating its potential effectiveness when combined with standard care. The results support the use of PSMA imaging for patient selection and highlight the advantages of a short treatment regimen.
Read more →TLXActivities Report and Appendix 4C for the quarter ended 30 September 2023
Telix Pharmaceuticals reported a strong performance for Q3 2023, achieving positive operating cash flow for the fourth consecutive quarter. The company experienced a 13% increase in U.S. sales of its imaging agent Illuccix, contributing to a total revenue of $133.6 million. Key developments include the initiation of the ProstACT GLOBAL study and progress in regulatory filings for its renal and brain cancer imaging agents.
Read more →TLXTelix reports fourth consecutive quarter of positive operating cash flow Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities...
Telix Pharmaceuticals Limited reported its Appendix 4C quarterly cash flow report for Q3 2023, demonstrating its fourth consecutive quarter of positive operating cash flow. The company's revenue grew notably with a 13% increase in U.S. sales of Illuccix, totaling $130.6 million. Additionally, Telix is advancing its clinical pipeline with the commencement of the ProstACT GLOBAL study and preparations for regulatory submissions for kidney and brain cancer imaging agents in the U.S. Despite ongoing challenges related to costs and regulatory risks, the overall momentum reflects strong market demand and operational stability.
Read more →TLXProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces positive preliminary results from the Phase I ProstACT SELECT study of...
Telix Pharmaceuticals has released positive preliminary results from the Phase I ProstACT SELECT study of TLX591, an rADC therapy for mCRPC. This study confirmed the safety and tolerability of TLX591 when administered in two cycles, establishing its potential utility in treating prostate cancer. The research included an evaluable population of 28 patients and confirmed the effective biodistribution of the candidate therapy. The company is continuing its investigation into TLX591 through the Phase III ProstACT GLOBAL study.
Read more →TLXTelix Quarterly Results and Investor Call / Webcast Notification
Telix Pharmaceuticals has announced the release date for its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ending September 30, 2023. The report will be made available on October 18, 2023, followed by an investor webcast scheduled for October 19, 2023. This initiative aims to keep investors informed about the company's financial status.
Read more →TLXHRH Princess Astrid of Belgium visits Telix’s New European Manufacturing Facility in Brussels South
Telix welcomed HRH Princess Astrid of Belgium to its new manufacturing facility in Brussels South, which is one of Europe's largest radiopharmaceutical production sites. The visit underscores the facility's role in meeting the growing demand for imaging and therapeutic agents in the EMEA region. The royal visit precedes an economic mission to Australia, showcasing collaboration between Belgium and Australia in the field of nuclear medicine.
Read more →TLXHRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix...
Telix Pharmaceuticals Limited has welcomed HRH Princess Astrid of Belgium to its newly inaugurated manufacturing facility in Brussels South. The facility, spanning 2,800 square meters, is positioned in Belgium's Radiopharma Valley and is one of Europe's largest radiopharmaceutical production sites. This visit precedes the Belgian Economic Mission to Australia, highlighting the collaboration between both countries. Telix's CEO emphasized the innovation-focused nature of the new site that aims to address significant medical needs in oncology and rare diseases.
Read more →TLXTelix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients
Telix, Eckert & Ziegler, and RefleXion Medical have announced a collaboration to develop Satellite Hot Labs (SHLs) for the radiolabeling of BioGuides used in biology-guided radiotherapy for prostate cancer. This initiative aims to enhance access to Gallium-68 PSMA-11, improving treatment options for all stages of prostate cancer. The collaboration leverages the strengths of each company to innovate in radiotherapy.
Read more →TLXTelix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
Telix Pharmaceuticals will present new data from its Phase III ZIRCON study at the EANM Congress in Vienna. The study focuses on TLX250-CDx for clear cell renal cell carcinoma. Additionally, Telix will showcase its theranostic pipeline and innovations in AI for cancer imaging. The event will feature several oral presentations and a sponsored symposium.
Read more →TLXTelix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the 36th...
Telix Pharmaceuticals Limited (ASX: TLX) will present new data from its pivotal Phase III ZIRCON study during the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna. The presentations will include details on the efficacy of TLX250-CDx in diagnosing clear cell renal cell carcinoma, along with various initiatives in prostate cancer imaging and therapy. Telix's commitment to advancing therapeutics and its innovative use of AI will also be highlighted during the congress.
Read more →TLXJoin Telix at EANM 2023 to explore personalised diagnostics in urological cancers
Telix is set to host a symposium at the EANM 2023 in Vienna, focusing on personalized diagnostics in urological cancers. The event will feature expert speakers, including renowned professionals from various institutions, who will discuss advancements in nuclear medicine. Attendees will have the chance to engage in discussions and enhance their understanding of oncology.
Read more →TLXTelix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
Telix has announced its financial results for the first half of 2023, showcasing significant revenue growth driven by Illuccix sales, totaling $218.3 million. The company has achieved positive earnings on an adjusted EBITDAR basis, indicating successful commercialization. Looking ahead, Telix anticipates launching two new products for cancer imaging in 2024, contingent on regulatory approval.
Read more →TLXTelix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2023. All figures...
Telix Pharmaceuticals Limited announced its financial results for the half-year ending June 30, 2023, reporting significant revenue growth led by $218.3 million from Illuccix sales. The company has achieved positive earnings on an adjusted EBITDAR basis, marking its transition to a sustainable commercial stage. Looking ahead, Telix plans to launch two new imaging products for brain and kidney cancers in 2024 and anticipates continued growth in the global PSMA PET imaging market. The Managing Director highlighted the company's progress in therapeutic programs and upcoming clinical milestones.
Read more →TLXTelix Half-Year Results 2023 and Investor Call / Webcast Notification
Telix Pharmaceuticals will announce its financial results for the half-year ending June 30, 2023, on August 23, 2023. An investor webcast is scheduled for August 24, 2023, at 8:30 AM AEST, providing an opportunity for stakeholders to engage with the company's performance. Registration details for the webcast are available online.
Read more →TLXFirst Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Telix has initiated a pivotal Phase III study for TLX591-CDx (Illuccix) in China, focusing on prostate cancer imaging. The study will enroll up to 110 patients with biochemically recurrent prostate cancer to evaluate the diagnostic utility of the imaging agent. This study is crucial for future marketing authorization in China, following FDA approval in the U.S.
Read more →TLXFirst Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III...
Telix Pharmaceuticals Limited has announced the dosing of the first patient in its pivotal Phase III study of TLX591-CDx (Illuccix) for prostate cancer imaging in China. This prospective, open-label, single-arm study will involve up to 110 patients with biochemical recurrence of prostate cancer and aims to ensure that the diagnostic utility of TLX591-CDx is equivalent in Chinese and Western populations. The trial is necessary for supporting future marketing authorization of TLX591-CDx in China, following prior approvals by the FDA and other global regulatory agencies.
Read more →TLXFirst Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
Telix has announced the dosing of the first patient in the Phase I IPAX-2 study of TLX101, targeting newly diagnosed glioblastoma. This study aims to evaluate the safety and efficacy of TLX101 in combination with standard treatments. The trial follows encouraging results from the previous IPAX-1 study, which demonstrated safety and potential therapeutic effects.
Read more →TLXFirst Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company's...
Telix Pharmaceuticals Limited (ASX: TLX) has announced that the first patient has been dosed in the Phase I IPAX-2 study of TLX101, an investigational therapy for newly diagnosed glioblastoma patients. This study will evaluate the safety profile of TLX101 in combination with existing treatment options. The research builds on previous encouraging data from the IPAX-1 study, which demonstrated potential therapeutic benefits and a tolerable safety profile. Conducted at multiple sites across Australia, New Zealand, and Europe, the IPAX-2 study aims to further explore the efficacy of TLX101 in front-line glioblastoma therapy.
Read more →TLXTelix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
Telix Pharmaceuticals reported strong financial performance for Q2 2023, with a 19% increase in U.S. sales of Illuccix, contributing to total revenue of $120.7 million. The company achieved a positive operating cash inflow of $10.8 million, marking its third consecutive quarter of positive cash flow. Additionally, Telix is advancing regulatory applications for new imaging products and expanding its therapeutic pipeline.
Read more →TLXTelix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities...
Telix Pharmaceuticals Limited reported impressive results for Q2 2023, showcasing a continued trend of double-digit revenue growth primarily from sales of Illuccix. The company achieved a total revenue of $120.7M, with a significant 19% growth in U.S. sales. Telix also recorded its third consecutive quarter of positive operating cash flow, highlighting strong commercial performance. Additionally, they announced plans for marketing two new products focused on kidney and brain cancer imaging and opened a new European manufacturing facility in Brussels.
Read more →TLXFirst Patient Dosed in STARSTRUCK Study
Telix has initiated the STARSTRUCK study, dosing the first patient in a Phase I trial of TLX250 combined with Merck's peposertib. This study targets patients with solid tumors expressing CAIX, aiming to evaluate the safety and efficacy of the combination therapy. The hypothesis suggests that this approach may enhance treatment potency while reducing radiation doses.
Read more →TLXFirst Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the...
Telix Pharmaceuticals has announced that the first patient has been dosed in the Phase I STARSTRUCK study, which explores the safety and efficacy of TLX250 combined with Merck's peposertib in treating solid tumors that express CAIX. The study aims to assess this combination's potential to improve treatment outcomes for patients with advanced cancer. Preclinical data have suggested that this therapy may enhance the potency of radiation therapy while reducing necessary radiation doses. Up to 80 patients will participate across multiple sites in Australia.
Read more →TLXNew ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase ...
Telix Pharmaceuticals Limited announced positive results from its Phase III ZIRCON study of TLX250-CDx for clear cell renal cell carcinoma (ccRCC). The study demonstrated that TLX250-CDx PET/CT detected more lesions than conventional CT imaging, with robust overall sensitivity and specificity. The results were presented at the SNMMI 2023 Annual Meeting, emphasizing its potential utility for staging and monitoring high-risk patients. The company is also working on expanding access pathways for TLX250-CDx in the U.S. and Europe.
Read more →TLXTelix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's investigational prostate (prostate...
Telix Pharmaceuticals Limited announced it will present findings from its Phase III ZIRCON study, focusing on kidney cancer imaging, at the SNMMI 2023 Annual Meeting in Chicago. The company will also showcase its various investigational therapies, including its CAIX-targeting radionuclide therapy and FDA-approved prostate cancer imaging agent, Illuccix. This participation represents a significant opportunity for Telix to highlight its advancements in oncological imaging and therapy. Presentations will cover the efficacy of its diagnostic and therapeutic programs aimed at addressing unmet medical needs in cancer treatment.
Read more →TLXTelix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its...
Telix Pharmaceuticals has announced an agreement to acquire Lightpoint Medical, enhancing its capabilities in urologic cancer treatment. The acquisition includes the SENSEI radio-guided surgery technology, which is designed to improve cancer detection and treatment outcomes during surgical procedures. This strategic move is expected to align SENSEI with Telix's existing prostate cancer programs and expand its reach into various malignancies. The integration of Lightpoint's innovative AI-based capabilities will further bolster Telix's portfolio in this healthcare segment.
Read more →TLXTelix Urology Innovation Showcase to be held at The Yale Club, New York City Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company's briefing session for shareholders to...
Telix Pharmaceuticals Limited is set to hold a shareholder briefing session at The Yale Club in New York City on June 21, 2023. This session will allow shareholders to hear updates regarding the company's market disclosures and will feature discussions on its investigational products for renal cancer and prostate cancer. Notably, the event will be available via live webcast for broader participation. Telix aims to inform stakeholders about its progress and future plans in the biopharmaceutical landscape.
Read more →TLXFirst Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the...
Telix Pharmaceuticals announced the dosing of the first patient in its Phase II STARBURST study, which explores the application of the imaging agent TLX250-CDx in various solid tumors. The study aims to investigate CAIX expression across a range of cancer types, including aggressive and hard-to-treat tumors. This initiative follows promising preliminary data from earlier studies and aims to expand the utility of TLX250-CDx beyond clear cell renal carcinoma, leveraging its diagnostic and potential therapeutic applications.
Read more →TLXTelix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the following distinguished Key Opinion Leaders will be featured at ...
Telix Pharmaceuticals Limited is hosting an educational session for investors on June 21, 2023, at The Yale Club in New York City, featuring prominent Key Opinion Leaders in the fields of prostate and kidney cancer. The event will highlight Telix's urologic pipeline, including their commercial product Illuccix® and investigational therapies targeting prostate-specific membrane antigen and carbonic anhydrase IX. The session aims to provide an overview of the company’s growth strategy and product developments in the urology sector. Institutional investors and analysts are invited to attend, with registration required.
Read more →TLXTelix Opens European Radiopharmaceutical Production Facility Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research...
Telix Pharmaceuticals has inaugurated its new radiopharmaceutical production facility in Belgium's Wallonia region, which is among the largest in Europe. This 2,800 square meter site will primarily manufacture radioisotopes and clinical products to address increasing demand across the Europe, Middle East, and Africa regions. The facility is positioned to leverage Belgium's strengths in nuclear medicine, thanks to support from local government and a growing workforce. Telix aims for this site to not only boost its production capabilities but also act as a research and manufacturing hub for industry collaborations.
Read more →TLXTelix to Present at Jefferies Healthcare Conference Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be...
Telix Pharmaceuticals Limited announced that Dr. Christian Behrenbruch, its Managing Director and Group CEO, will present at the Jefferies Healthcare Conference in New York from June 7-9, 2023. The presentation is scheduled for June 7 from 12:30 PM to 12:55 PM EDT and will be available via a live webcast. Telix focuses on the development and commercialisation of radiopharmaceuticals and has a strong portfolio addressing unmet medical needs in oncology and rare diseases.
Read more →TLXTelix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it will host an education session for investors on Wednesday, June 21,...
Telix Pharmaceuticals Limited announced it will host an education session for investors on June 21, 2023, at The Yale Club in New York City. The session will highlight the company's urologic pipeline and feature a discussion on novel therapeutics, imaging agents, and technologies aimed at treating urological cancers. Key speakers will include members of the Telix leadership team and notable opinion leaders in the field.
Read more →TLXTelix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply...
Telix Pharmaceuticals has announced a partnership with Bayer AG to supply its imaging product, Illuccix®, for a global Phase III study focused on prostate cancer. The study will involve up to 750 patients and aims to evaluate the efficacy of darolutamide in combination with androgen deprivation therapy versus ADT alone. This collaboration showcases Telix's commitment to advanced prostate cancer imaging technology and may improve disease management through enhanced imaging methods. The use of PSMA-PET/CT in this context may provide significant benefits over conventional imaging techniques.
Read more →TLXFirst Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially...
Telix Pharmaceuticals Limited has announced the availability of its prostate cancer imaging agent, Illuccix, in Canada. The first patients have been successfully imaged using Illuccix at INITIO Medical Group in Burnaby, British Columbia. This marks a significant milestone for Telix, as Illuccix is the first PSMA-PET imaging agent to receive regulatory approval in Canada, joining its availability in Australia, New Zealand, and the United States. The agent is expected to address significant unmet medical needs for men diagnosed with prostate cancer, with a nationwide distribution facilitated by Isologic Innovative Radiopharmaceuticals.
Read more →TLXZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON...
Telix Pharmaceuticals Limited (ASX: TLX) presented new positive data from its pivotal Phase III ZIRCON study on TLX250-CDx at the AUA Annual Meeting. The study demonstrated an 84% sensitivity for detecting clear cell renal cell carcinoma in masses 2cm or smaller. This high accuracy reinforces the clinical utility of TLX250-CDx, especially in challenging diagnostic scenarios. Telix is implementing expanded access programs in the US and named patient programs in Europe to bring this imaging agent to the market, pending regulatory approvals.
Read more →TLXTelix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with the...
Telix Pharmaceuticals Limited announced the acquisition of Dedicaid GmbH to enhance its artificial intelligence capabilities for medical imaging. This acquisition allows Telix to add predictive analytics to its Telix AI™ platform, which is being developed for enhanced efficiency and standardization in imaging workflows. The financial terms involve an upfront payment and additional contingent payments based on regulatory success. The transaction is poised to accelerate the development of new clinical decision support systems while aiming for FDA and CE Mark approvals within the year.
Read more →TLXTelix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities...
Telix Pharmaceuticals Limited reported its financial results for Q1 2023, achieving its first revenue quarter of $100M, driven primarily by its Illuccix product. The company noted a strong demand for its imaging agent in the U.S., with FDA approval for an expanded indication. Additionally, Telix posted a second consecutive quarter of positive operating cash flow, indicating financial stability. The company is focused on expanding its product offerings and regulatory approvals in multiple regions.
Read more →TLXOlaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an...
Telix Pharmaceuticals Limited announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly. The company demonstrated proof-of-concept for using olaratumab to deliver both diagnostic and therapeutic radiation to tumors, particularly for Soft Tissue Sarcoma. With encouraging results, Telix plans to advance to first-in-human clinical trials. Olaratumab could represent a significant innovation in cancer treatment. This development may leverage the existing safety profile from prior studies to enhance future applications in oncology.
Read more →TLXFDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a ...
Telix Pharmaceuticals has received FDA approval for the expanded use of its imaging agent Illuccix, enabling it to help select patients with metastatic prostate cancer for PSMA-directed radioligand therapy. This approval marks a significant advancement in patient management, combining accurate imaging with an efficient distribution network. The VISION Phase III study demonstrated the effectiveness of Illuccix in identifying suitable candidates for treatment. With an estimated 32,000 patients in the U.S. potentially benefiting annually, this move could greatly enhance the quality of prostate cancer care.
Read more →TLXTelix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in Game Changing Session at EAU Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON...
Telix Pharmaceuticals Limited (ASX: TLX) has announced positive results from its Phase III ZIRCON study of TLX250-CDx, concerning clear cell renal cell carcinoma. The findings were presented during a 'Game Changing' session at the recent EAU Congress by Prof. Dr. Peter Mulders. The results suggest significant potential for TLX250-CDx, particularly in diagnosing small renal masses. Telix aims to broaden access to this therapy through expanded studies and programs in the United States and Europe.
Read more →TLXTelix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting...
Telix Pharmaceuticals Limited will showcase additional data from its pivotal Phase III ZIRCON study of TLX250-CDx at the 38th Annual European Association of Urology Congress in Milan. This study focuses on clear cell renal cell carcinoma, and the session is considered 'Game Changing' by the EAU's Scientific Congress Office. The company will also present data on TLX250-CDx's potential applications in bladder cancer, as well as there concurrent preclinical evaluations. These efforts highlight Telix's commitment to advancing innovation in urologic oncology.
Read more →TLXTelix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended 31 December 2022. All ...
Telix Pharmaceuticals Limited announced significant financial results for the year ending December 31, 2022, highlighting a remarkable 20-fold increase in revenue during its first year of commercial sales. The company successfully launched its first commercial product, Illuccix, and achieved positive results from its Phase III ZIRCON study for TLX250-CDx, a kidney cancer imaging agent. Telix’s strong financial management has positioned it to transition to cash flow positive while investing in its late-stage pipeline. Looking ahead, Telix aims to prepare regulatory filings for new imaging agents targeting kidney and brain cancers.
Read more →TLXDetailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become ...
Telix Pharmaceuticals Limited announced positive results from its Phase III ZIRCON trial, demonstrating that TLX250-CDx meets both primary and secondary endpoints for the detection of clear cell renal cell carcinoma (ccRCC). The trial showed high sensitivity and specificity, with results presented at the ASCO GU Symposium. The imaging agent has the potential to address unmet medical needs in the diagnosis and management of ccRCC. Additionally, the favourable safety and tolerability profile of TLX250-CDx was confirmed, showing promise for its clinical application.
Read more →TLXTelix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with...
Telix Pharmaceuticals Limited has announced the successful completion of its joint research project with Heidelberg University Hospital. The project has resulted in the creation of a generator-based theranostic compound for urologic oncology, specifically targeting PSMA, which has been validated through pre-clinical and initial human evaluations. The findings have been published in the Journal of Nuclear Medicine, and discussions are underway to advance the compound into Phase I clinical trials. This innovative approach aims to decentralize drug manufacturing and expand access to new therapeutic applications.
Read more →TLXTelix Reports Fourth Quarter 2022 Financial Results 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and...
Telix Pharmaceuticals Limited reported a strong financial performance for Q4 2022, achieving $76.8 million in revenue, marking a 43% increase compared to the previous quarter. The company also celebrated its first net operating cash inflow of $1.6 million, reflecting improved sales and expense management. Notably, Telix received regulatory approval for its imaging agent, Illuccix, in Canada and anticipates further clinical advancements, including promising data from its TLX250-CDx renal cancer study, which may redefine diagnostic protocols.
Read more →TLXPresentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 – ...
Telix Pharmaceuticals Limited (ASX: TLX) is set to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. The company disclosed an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M from sales of its Illuccix kit for prostate cancer imaging, marking a 39% increase from the previous quarter. Group CEO Dr. Christian Behrenbruch expressed satisfaction with the strong sales momentum and highlighted the company's overall progress in commercial activities and product pipeline expansion.
Read more →TLXZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will...
MELBOURNE , Australia and INDIANAPOLIS , Dec. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118 ) of TLX250-CDx ( 89 Zr-DFO-girentuxim
Read more →TLXTelix Announces Executive Leadership Appointments Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting ...
MELBOURNE, Australia , Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.
Read more →TLXIlluccix® Available on High Activity Gallium Generator Technology to Meet High Demand Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide...
INDIANAPOLIS , Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix ® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gall
Read more →TLXFirst Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated ...
MELBOURNE, Australia , Nov. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in
Read more →TLXTelix Acquires Optimal Tracers Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Sacramento-based Northern...
MELBOURNE , Australia and INDIANAPOLIS, Ind. , Nov. 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Sacramento -based Northern California PET Imaging Center (NCPIC) to acquire Optimal
Read more →TLXTelix to Present at Jefferies London Healthcare Conference 2022 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and...
MELBOURNE, Australia , Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Chr
Read more →TLXTelix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has...
Summary of Study Outcomes MELBOURNE, Australia , Nov. 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces highly positive top-line results from the pivotal Phase III ZIRCON study ( Zi rconium in R enal C ancer On cology, NCT038491
Read more →TLXTelix Reports Third Quarter 2022 Financial Results Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities...
MELBOURNE, Australia , Oct. 19, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AU
Read more →TLXTLX250-CDx Indication Expansion: Preliminary Data Presented at EANM OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect...
MELBOURNE, Australia , Oct. 18, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx ( 89 Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and
Read more →TLXTelix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today announced a collaborative development and reseller agreement with GE...
MELBOURNE, Australia , Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today announced a collaborative development and reseller agreement with GE Healthcare to supply its investigational positron emission tomography (PET) imaging rad
Read more →TLXChinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center...
MELBOURNE, Australia , Oct. 16, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) appli
Read more →TLXHealth Canada Approves Illuccix® for Prostate Cancer Imaging Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium...
MELBOURNE, Australia , Oct. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium ( 68 Ga) gozetotide injection] for use in staging and re-staging intermediate
Read more →TLXEANM Presentations to Showcase New Data and Developments in Telix's Theranostics Pipeline Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the European Association of Nuclear Medicine (EANM)...
MELBOURNE , Australia and LIEGE, Belgium , Oct. 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the European Association of Nuclear Medicine (EANM) Annual Congress to be held in Barcelona from 15-19 October, 20
Read more →TLXChinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center...
MELBOURNE, Australia , Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study
Read more →TLXFirst Patient Enrolled in ProstACT TARGET Study Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia, today...
MELBOURNE, Australia , Sept. 26, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia , today announce that a first patient has been enrolled in the Phase II ProstACT TARGET
Read more →TLXFinal IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[...
MELBOURNE, Australia , Sept. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ 131 I] iodo-phenylalanine, or 131 I-IPA) in combination with external beam rad
Read more →TLXTelix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer...
MELBOURNE, Australia , Aug. 1, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress
Read more →TLXBAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging The PSMA-PET[1] imaging agent Illuccix® from Telix Pharmaceuticals Limited (Telix) has been used in combination with the uEXPLORER®, a first-of-its...
Telix and BAMF Health use Illuccix® (kit for the preparation of Gallium Ga 68 gozetotide injection) for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging GRAND RAPIDS, Mich. and INDIANAPOLIS , July 27, 2022 /PRNewswire/ -- The PSMA-PET [1] imaging
Read more →TLXTelix Reports Second Quarter 2022 Financial Results Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities...
MELBOURNE, Australia , July 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2022 . All figures are in AUD$ unless othe
Read more →TLXZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the...
MELBOURNE, Australia , July 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON ( Zi rconium in R enal C ancer On cology, NCT038
Read more →TLXKevin Richardson appointed as CEO, Telix Americas Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that Kevin Richardson, a senior global executive with a career...
MELBOURNE and INDIANAPOLIS , July 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that Kevin Richardson , a senior global executive with a career focus on sales, marketing and business operations in the oncology and rad
Read more →TLXTelix and Invicro Advance AI Partnership Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, ...
MELBOURNE, Australia and BOSTON , June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to deve
Read more →TLXJubilant Radiopharma Joins Illuccix® Pharmacy Partner Network Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for...
MELBOURNE, Australia and INDIANAPOLIS , June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selec
Read more →TLXTelix and RefleXion Expand Partnership for Prostate Cancer Treatment Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the...
MELBOURNE , Australia and INDIANAPOLIS , June 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. ( Hayward, California , U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreemen
Read more →TLXTelix to Present at Jefferies Healthcare Conference Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on the development and commercialisation of...
MELBOURNE, Australia and INDIANAPOLIS , June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiati
Read more →TLXTelix Showcasing Innovation in Theranostics at SNMMI Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging...
MELBOURNE , Australia and INDIANAPOLIS , June 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held in Vancouver from June 11-14
Read more →TLXIlluccix® Granted Transitional Pass-Through Payment Status Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of ...
INDIANAPOLIS , May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment
Read more →TLXFirst Patient Dosed in Phase II Renal Cancer Theranostics Study Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study...
MELBOURNE, Australia and INDIANAPOLIS , May 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (
Read more →TLXFirst Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first commercial doses of its prostate cancer imaging agent, Illuccix®...
Physicians in Indiana , New York City , and Washington are among the first to administer Illuccix ® – demonstrating coast-to-coast availability of this new imaging agent Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American m
Read more →TLXProstACT Update: TARGET Study Ethics Approval Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate...
MELBOURNE, Australia , April 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate cancer antibody therapy candidate TLX591 ( 177 Lu-DOTA-rosopatamab), in patient
Read more →TLXTelix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab Telix Pharmaceuticals Limited (ASX: TLX, Telix , the Company ) today announces that it has entered into a licence agreement with Eli Lilly and...
MELBOURNE, Australia and INDIANAPOLIS , April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwi
Read more →TLXCommercial Launch: Illuccix® Now Available to Order in the United States Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of...
MELBOURNE, Australia and INDIANAPOLIS , April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that its prostate cancer imaging agent, Illuccix ® (kit for preparation of gallium Ga 68 gozetotide), also known as 68 Ga-PSMA-11 injection
Read more →TLXChange of Composition of the Telix Board of Directors Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Tiffany Olson has been appointed to the Board, as a U.S.-based...
MELBOURNE, Australia and INDIANAPOLIS , March 30 , 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent, Non-Executive Director. Ms. Olson currently serve
Read more →TLXNew Video Series PSMA PET/CT TODAY Discusses the Future of Prostate Cancer Care with Leading Experts Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring...
MELBOURNE, Australia and INDIANAPOLIS , March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT [1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagn
Read more →TLXTelix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted...
MELBOURNE , Australia and INDIANAPOLIS , March 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 ( 90 Y-besilesomab),
Read more →TLXTelix Advances Development of Glioblastoma Therapy Program Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma...
MELBOURNE, Australia , March 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma multiforme (GBM) therapy candidate TLX101 into the next stage of clinical developm
Read more →TLXTelix Radiopharmaceutical Production Facility Buildout Commences
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the
Read more →TLXTelix Enters Commercial Distribution Agreement for Illuccix in Australia
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Telix’s prostate cancer imaging pr
Read more →TLXTelix and SHINE partner for Lutetium-177 Supply
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.
Read more →TLXTelix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) for highly pure no-carrier-add
Read more →TLXTelix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Athens-based BIOKOSMOS S.A. (BIOKOSMOS) for Telix’s
Read more →TLXTelix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective
Read more →TLXFDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix® | Telix Pharmaceuticals
The FDA has approved Telix's Illuccix, a prostate cancer imaging product, enhancing access to PSMA-PET imaging across the U.S. This approval marks a significant advancement in diagnostic tools for prostate cancer, offering flexible preparation and distribution options for healthcare providers.
Read more →TLXTelix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Madrid-based NUCLIBER S.A. Spain (NUCLIBER) for Teli
Read more →TLXTelix Establishes Commercial Hub in Geneva, Switzerland
MELBOURNE, Australia and GENEVA, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH. T
Read more →TLXTelix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Bologna-based RADIUS S.r.l. (Radius) for Telix’s p
Read more →TLXTelix In-Licences Novel Tumour Microenvironment PET Tracer
MELBOURNE, Australia and LI GE, Belgium, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive licence agreement for a novel positron emission tomography (PET) radiotracer that origina
Read more →TLXTelix Expands Prostate Cancer Activity with GenesisCare Collaboration
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program that significantly extend the evaluation of Telix’s TLX591 antibody-directed 177Lu (
Read more →TLXTelix and Merck to Commence Pan-Cancer Clinical Combination Studies
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (‘Merck’), to conduct combination studies with
Read more →TLXTelix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Me
Read more →TLXTelix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB
MELBOURNE, Australia and ADELAIDE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has extended its previously announced partnership with AusHealth Corporate Pty Ltd (‘AusHealth’) relating to APOMAB®
Read more →TLXTelix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital (GOSH) has received UK research ethics approval to commence a Phase II academic stud
Read more →TLXTelix to Present at the 2021 Jefferies Virtual Healthcare Conference
MELBOURNE, Australia and NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021. The present
Read more →TLXTelix and Monrol Expand Alliance to Include Lutetium Supply
MELBOURNE, Australia and ISTANBUL, Turkey, May 10, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered a global clinical supply agreement with Istanbul-based Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) for
Read more →TLXTelix Commences Phase III Clinical Trial of Prostate Cancer Therapy
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Thera
Read more →TLXTelix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President
MELBOURNE, Australia and HERSTAL, Belgium, May 02, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Mr. Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa
Read more →TLXTelix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix
MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufa
Read more →TLXTelix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into an agreement with Scintec Diagnostics GmbH (‘Scintec’) to acquire TheraPharm GmbH (‘TheraPharm’), a Swiss-G
Read more →TLXTelix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘Ch
Read more →TLXTelix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for TLX591-CDx (Kit for
Read more →TLXTelix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
MELBOURNE, Australia and PALO ALTO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use
Read more →TLXTelix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging
TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has entered a Memorandum of Understanding (MOU) with ATOX Co., Ltd. (‘ATOX’), the exc
Read more →TLXTelix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
MELBOURNE, Australia and LI GE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (68Ga-PSMA-11 Injection) for the i
Read more →TLXTelix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MT
Read more →TLXTelix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR), to
Read more →TLXTelix Pharmaceuticals to Launch Japanese Renal Cancer Imaging Study
MELBOURNE, Australia and KYOTO, Japan, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceu
Read more →TLXTelix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR)
Read more →TLXTelix Pharmaceuticals and German Cancer Research Center (DKFZ) Enter into Collaboration and Option Agreement for Image-Guided Prostate Surgery
MELBOURNE, Australia and HEIDELBERG, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radioph
Read more →TLXTelix Pharmaceuticals and Grupo RPH Sign LATAM Manufacturing and Distribution Agreement
MELBOURNE, Australia and PORTO ALEGRE, Brazil, July 03, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiop
Read more →TLXTelix Pharmaceuticals and PI Medical Sign Distribution Agreement for the Netherlands
MELBOURNE, Australia and RAAMSDONKSVEER, Netherlands, July 02, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted
Read more →TLXTelix Pharmaceuticals to Present at Jefferies Healthcare Conference
MELBOURNE, Australia and NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceutica
Read more →TLXTelix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial Using Advanced Imaging of Prostate Cancer for Radiotherapy
MELBOURNE, Australia and ATLANTA, May 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals
Read more →TLXTelix Group Expands Prostate Imaging Capability through ININ Technology Partnership
MELBOURNE, Australia and LIEGE, Belgium, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Advanced Nuclear Medicine Ingredients SA (“ANMI”), a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX:TLX, “Telix”) today announced that it has completed the in-licensing of 99mtechnetium-EDDA
Read more →TLXTelix Pharmaceuticals Launches illumet™ Microsite (Kit for the Preparation of 68Ga-PSMA)
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix Group”, “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals o
Read more →TLXTelix and Nihon Medi-Physics to Collaborate on Actinium Renal Cancer Therapeutics
MELBOURNE, Australia, KYOTO, Japan and TOKYO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radioph
Read more →TLXTelix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA
MELBOURNE, Australia, BRUSSELS and LI GE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted ra
Read more →TLXTelix and ANMI Expand PSMA Imaging Partnership
MELBOURNE, Australia and LI GE, Belgium, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmac
Read more →TLXTelix and Cyclotek Enter into Manufacturing Partnership for Kidney Cancer Imaging
MELBOURNE, Australia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecu
Read more →TLXTelix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
INDIANAPOLIS and COLUMBUS, Ohio, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (US) Inc. (“Telix USA”), a subsidiary of Telix Pharmaceuticals Limited (ASX:TLX), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products
Read more →TLXTelix Completes Acquisition of Atlab for Prostate Cancer Program
MELBOURNE, Australia and NANTES, France, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced completion of the acquisition of Atlab Pharma SAS (“Atlab”). The option to acquire Atlab for the consideration of USD $10m (in cash
Read more →TLXTelix Pharmaceuticals, University of Melbourne and Peter Mac to Collaborate on Colorectal Cancer
MELBOURNE, Australia, Aug. 24, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”) has today announced a research collaboration with the University of Melbourne to investigate the use of targeted radiopharmaceuticals or “molecularly-targeted
Read more →TLXTelix and Nihon Medi-Physics to Collaborate on Renal Cancer Imaging for the Japanese Market
MELBOURNE, Australia and KYOTO, Japan and TOKYO, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radi
Read more →TLXTelix Pharmaceuticals and JFE Progress Japanese Manufacturing Partnership
MELBOURNE, Australia and TOKYO, July 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or
Read more →TLXTelix and Isologic conclude manufacturing agreement for North America
MELBOURNE, Australia and MONTREAL, June 25, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix Group”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmac
Read more →TLXTelix Pharmaceuticals and Osaka University receive Japan Science and Technology Agency Funding for Alpha Nuclide Research
KYOTO and OSAKA, Japan, May 30, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molec
Read more →TLXTelix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership
MELBOURNE, Australia and NANTES, France, April 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharma
Read more →TLXTelix Pharmaceuticals and Radboud University Medical Centre Conclude Clinical Collaboration Agreement
MELBOURNE, Australia and NIJMEGAN, The Netherlands, March 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted
Read more →TLXTelix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives
MELBOURNE, Australia and KYOTO Japan, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceutica
Read more →TLXTelix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
MELBOURNE, Australia and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals
Read more →TLXTelix Pharmaceuticals and JFE Announce Japanese Radiopharmaceutical Manufacturing Partnership
MELBOURNE, Australia and TOKYO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or
Read more →TLXTelix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc.
MELBOURNE, Australia and INDIANAPOLIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceutic
Read more →TLXTelix Pharmaceuticals Limited Lists on the Australian Securities Exchange
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecular
Read more →TLXTelix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targete
Read more →TLXTelix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging
MELBOURNE, Australia and LI GE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecu
Read more →TLXTelix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)
MELBOURNE, Australia, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted ra
Read more →TLXTelix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
MELBOURNE, Australia and SAN FRANCISCO, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company) is pleased to announce the conclusion of a collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET im
Read more →TLXTelix Pharmaceuticals Acquires Glioblastoma Program from Therapeia
MELBOURNE, Australia and DRESDEN, Germany, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”) is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”). Telix will add Therapeia’s ACD-101 theranostic program for glio
Read more →TLXTelix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer
MELBOURNE, Australia and NANTES, France, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS (“Atlab”). Under the terms of the agreement, Tel
Read more →Competitive Position
How TLX ranks across every disease it competes inCompetitive Position is a premium feature
See how TLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial